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PREVALENCE OF IRREVERSIBLE AIRFLOW OBSTRUCTION 
AMONG CHRONIC ASTHMATICS IN 
GOVERNMENT ROYAPETTAH HOSPITAL 
 
BACKGROUND: 
 Asthma is a chronic inflammatory airway disorder characterized 
by airway hyper responsiveness and reversible airflow obstruction. Subgroups 
of asthma patients develop airflow obstruction that is irreversible or only 
partially reversible and experience an accelerated rate of lung function 
decline. Airway remodelling has been associated with increased disease 
severity. Irreversible and partially reversible air flow obstruction(COPD 
pattern) in asthmatics have been associated with longer duration, reduced 
pulmonary function early in life, frequent exacerbations, smoking, continuing 
exposure to a sensitizing agent, and adult-onset asthma and lack of use of 
inhaled corticosteroids early in the course of the disease.The need to identify 
this pattern using pulmonary function test is always overlooked. This study 
looks at those patients with long duration asthma with a irreversible and a 
partially reversible airflow obstruction and analyses the risk factors that 
potentiate this phenotype in asthma patients and thereby gives clues towards 
prevention of lung function decline in asthmatics. 
OBJECTIVE: 
The objectives of this study are to determine the prevalence of 
irreversible air flow obstruction in chronic asthmatics using spirometry and to 
assess the risk factors contributing to the development of  irreversible airflow 
obstruction in chronic asthmatics. 
MATERIALS AND METHODS: 
Patients who were aged more than 18years with  asthma duration >10 years 
were included. The patients had their defined clinically by Diurnal variation of 
symptoms, predominantly nocturnal symptoms ,seasonal aggravation of 
symptoms,presence of nasal polyps,Allergic tendencies to known 
allergens,positive family history, complete relief of the symptom in the 
past/present with nebulisation. Patients were thoroughly instructed on the use of 
spirometer and with the informed consent a FEV1, FVC and FEV1/FVC values 
were obtained using spirometer before and after salbutamol nebulisation. 
Steroid trail (40mg for 2 weeks) and the values were assessed after 2 weeks. 
Irreversible airflow obstruction was defined as a failure to increase the FEV1 by 
>12% or 200ml. The correlation of various factors like smoking, lack of steroid, 
duration of asthma and age at onset of asthma with the reversibility of airflow 
obstruction was assessed in the study group. 
RESULTS: 
 Irreversible airflow obstruction was prevalent (50%)in the study 
population. Smoking, duration of asthma, severity of asthma were significantly 
associated with irreversible airflow obstruction (p<.05).  lack of steroid use and 
age at onset of asthma had statistically insignificant association(p>.05). 
CONCLUSION: 
Although airflow obstruction in asthma is reversible, longer duration of 
asthma, smoking, severe type of asthma was found to be related to irreversible 
pattern of obstruction in asthmatics. Also asthma when irreversible mimicked 
clinically as COPD. Thus this study favours asthma as a predisposing/risk factor 
for COPD. The study also emphasis the importance of using spirometry in 
diagnosing and monitoring asthma. The recognition of this pattern among 
asthmatics help in planning the treatment as in outpatient visits and in 
Emergency rooms 
KEY WORDS: Asthma, irreversible airflow obstruction, spirometry ,FEV1, 
FVC. 
 
 
 
 
  
 
  
 
 
 
 
         
 
            INTRODUCTION 
 
 
 
 
 
 
 
 
                                           INTRODUCTION 
                     Asthma, a condition characterised by airway inflammation has 
been one of the oldest known disease that mankind has suffered heavily in terms 
of morbidity and economic burden. As the industrialisation peaked, so did the 
incidence of the disease. In spite of having  a number of evidence to establish 
the aetiology, the natural course and pathology of this disease, and even though 
there is working definition for the disease, there are still lacunae  that fail to 
meet the satisfaction of even those who pioneer  the field. It is for this reason 
probably a complete cure is also a goal yet to be achieved. Although the current 
definition, sees asthma as a completely reversible airflow limitation a 
considerable set of population land up with irreversible airflow limitation in 
their course of life. It is with this background this study has been taken, to 
identify the set of population with irreversible airflow limitation and the factors 
that operate to make this condition an irreversible one. 
HISTORIC PRELUDE: 
            The term Asthma was obtained from the Greek word “aazein” which 
means to pant and to breath with open mouth or sharp breath. Descriptions 
about the disease date back to an era before Christ, the earliest by Hippocrates. 
The Greek physician Galen(2
nd
 century) in his publishing has described about 
the disease
[1]
.  Moses Maimonides (12
th
 century), an Egyptian physician, wrote 
in his book Treatise of Asthma that his observations of the symptoms in 
asthmatics were seasonal and it mostly started in the cold months as common 
cold and progressively increased in severity which makes the patient hungry for 
air and cough until he cleared his chest of sputum. The warm months were 
relatively free of symptoms. Other suggestions proposed by him were to restrict 
heavy medications, and sexual activity. Sleep, fluids and chicken soup were 
encouraged. Jean Baptiste Van Helmont (16
th
 century), a Belgian chemist, also a 
renowned physician of his period was the first to propose that asthma originated 
in the lung pipes. The Egyptians practised inhalational therapy by heating herbs 
over the bricks and inhaling the fumes from it. Chinese practised certain native 
herbs which had ephedrine as an ingredient in them thus facilitating the beta 
agonistic action. Bernardino Ramazzini (17th century) was the first to describe 
the exercise- induced asthma. He also described the association between 
asthma and organic dust. Asthma was dealt as a psychosomatic disease till the 
early decades of 20th century. Only after 1960 was the inflammatory pathology 
of the disease recognised and anti-inflammatory medications were started. 
EPIDEMIOLOGY: 
GLOBAL BURDEN: 
235 million people across the world have Asthma. The prevalence of 
asthma is estimated to increase by 50% globally every decade
 [2]
. An estimated 
increase of 100 million asthmatics is expected around 2025 owing to the 
expected rise in urban population from 45%-60%
 [2]
. 
 The maximum prevalence rates of asthma population are found in Great 
Britain and New Zealand. The prevalence rates in both these countries 
approaching 15-20% respectively 
[2]
. Asthmatic prevalence rate has increased 
two times the previous rates in the last ten years in Western Europe
 [4]
. Japan has 
seen a threefold rise in the asthma population over the last decade
 [2]
. 
  With the increasing urbanisation and westernisation trends in the 
developing countries like Africa, Central and South America, Asia, and the 
Pacific
 [2]
, the incidence of asthma has also started to increase. Prevalence rates 
are high in South American countries like Brazil, Costa Rica and Peru.  In these 
regions the rates are in the range of 10-15%
 [2]
. Asian countries such as China 
and India have reported lower prevalence rates (5-10%)
 [3]
 when compared to 
the European countries. But these two countries increase the global burden in 
terms of number of patients (absolute)
 [5]
.  
According to the WHO report around two hundred and fifty thousand 
people died in the year 2004-2005 due to asthma.  
An estimated disability-adjusted life year (DALYs) is around 15 million 
per year due to asthma
 [6]
. The costs of treating Asthma are higher than the cost 
for treating chronic infections like tuberculosis and HIV/AIDS added together
 
[7]
. Western countries suffer a loss from $300 to $1,300 per patient in a year for 
treating asthma
 [8]
.  
 Cost of treating asthma was found to be higher in the moderate and 
severe asthmatics than the mild asthmatics 
[9]
.Improper control of asthma has 
been found to be the detrimental element in raising the cost of treating asthma
 
[10]
. Western countries have a strict agenda for the control of the disease and 
have the majority of their asthma population (70%) in the mild category and 
thus have their cost cut down in managing the severe group.  Treating Asthma 
exacerbations have been found to be three and half times more costly than 
treating someone without exacerbations
 [11]
. 
ASTHMA BURDEN IN INDIA: 
               The epidemiological data on asthma are low in India. It is presumed 
that India has low prevalence rate of Asthma rates, although recent numbers 
shows that the actual prevalence is higher than what was initially thought 
[5]
.The 
prevalence of asthma in the total population is 3%(30 million) and the adult 
population (over 15 yrs) contributed 2.4% of the total population. 
                   The National Family Health Survey (NFHS)-3 conducted a cross 
sectional study to find out the prevalence rates of asthma in India. The gender 
wise distribution of asthma was almost similar amounting to 1,696 and 1,627 
per 100,000 respectively
 [12]
. The prevalence rate increased with age. Prevalence 
of asthma is higher in rural areas than urban areas. It is also less common in 
men than women. Male asthmatics are more clustered in the lower economic 
sections than the higher economic sections. Prevalence rates topped among 
people with <five years of schooling (2,283 /100,000 in women and 
2,640/100,000 in men). People with no education had a relatively lesser 
prevalence (1,914/ 100,000 in women and 2,440/ 100,000 in men)
[12]
. 
            Amongst the individual states the North east regions of India were found 
to have high prevalence rates. The prevalence among women was found to be 
the lowest in Himachal Pradesh (384/100000) population and highest in Tripura 
(5924/100000).  Women asthmatics over 1000/100000 population were seen in 
23 states and 5 states showed more than 3000/100000 population. The states 
were: West Bengal, Kerala, Mizoram, Tripura and Sikkim. Amongst men 
Jharkhand had the lowest prevalence (407/100000) and Tripura the highest 
(5086/100000). Only two states namely West Bengal and Tripura had a male 
asthmatic population of over 3000/100000. 
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DEFINITION OF ASTHMA: 
                The definition of asthma as per the global initiative of asthma 
[13]
 is as 
follows  
       Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a role, in particular, mast cells, eosinophils, T 
lymphocytes, macrophages, neutrophils, and epithelial cells. In susceptible 
individuals, this inflammation causes recurrent episodes of wheezing, 
breathlessness, chest tightness, and coughing, particularly at night or in the 
early morning. These episodes are usually associated with widespread but 
variable airflow obstruction that is often reversible either spontaneously or with 
treatment. The inflammation also causes an associated increase in the existing 
bronchial hyperresponsiveness to a variety of stimuli. 
RISK FACTORS: 
There are numerous risk factors associated with development of 
asthma. They may be isolated or may overlap in bringing out the phenotype of 
the disease. The risk factors known to be associated with asthma are as 
follows. 
            1)positive family history of atopy 2)low/high birth  weight 3)prematurity 
4)maternal smoking  during  pregnancy 5) high intake of salt  6) pet ownership 
7)childhood viral infection 8)obesity
[14] 
ATOPY AND ASTHMA:        
         Amongst these risk factors family history of atopic disease is the strongest 
of all risk factors
 [15]
. Increase in the risk of developing allergic rhinitis is 
fivefold and the risk of developing asthma is threefold to fourfold in a person 
with family history of atopy
[16] 
. In children, both positive skin tests and 
increases in total serum IgE are strongly associated with asthma
 [17]
. Serum IgE 
correlates strongly with bronchial hyperresponsiveness
[18]
.  
 Asthma may be categorised as follows
 [19] 
Figure 1: Classification of asthma
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EXTRINSIC ASTHMA: 
 It is due to the response of the immune system to inhaled allergens such as 
pollen, dust particles, animal dander, ozone (OUTDOOR ENVIRONMENT) or 
house mite, cats, dogs, molds. (INDOOR ENVIRONMENT). 
     
     Exposure to mite in the household increases the risk of developing asthma in 
a dose dependent manner
 [20] 
. A modest control of mites in the household 
reduces the incidence of asthma up to 8 years of life
 [21]
. 
INTRINSIC ASTHMA:  
               It is due to the response of immune system, to nicotine and other 
chemicals inhaled while smoking cigarette, to emotional factors like laughter 
and stress and when on NSAIDs particularly aspirin intake. 
HYGIENE HYPOTHESIS: 
               The most exciting theory proposed for explaining the early childhood 
infection as a protective factor in preventing asthma is the “hygiene hypothesis." 
It states as  
        “The rise in allergies in children is an unintended consequence of the 
success of domestic hygiene in reducing the rate of infections in early 
childhood”.  
       Thus according to this theory the more the hygienic practice, the more the 
medical and social changes and the smaller the family size becomes, less is the 
chance of childhood infections in the population and the chances of developing 
asthma increases especially in those with family history of atopy. Possible 
explanation for this hypothesis is immune selection through which the Th2 cells 
are selected over the Th1 cells (normally predominant) in the mucosal surfaces. 
The immunologic milieu at the fetal—maternal interface is towards a Th2 
phenotype, and this immune bias is carried into neonatal life
[22]
. Unless the 
pattern of immune response in the airways is "reprogrammed" toward a Th1 
pattern, the infant will have a prolonged high-risk window for allergic 
sensitization to aeroallergens
[23]
. The principal impetus to this reprogramming of 
the mechanisms of the immune response toward a normal Th1/Th2 balance is 
hypothesized to be contact with pathogenic and commensal microorganisms at 
the body's mucosal surfaces
 [24]
. 
Figure 2: Factors determining asthma development 
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VIRAL RESPIRATORY TRACT INFECTIONS AND ASTHMA: 
  That viral infection of the airways might have a role in inducing asthma. 
Childhood history of bronchiolitis was a major predictor of airway hyper 
responsiveness and allergic sensitivity later in life
 [25]
.  Upper respiratory 
infections (URIs) were noted to occur 1 to 2 months prior to the onset of 
allergic sensitization in most of the children according to a large longitudinal 
study
 [26]
. The number of URIs in infancy is inversely related to the risk of 
asthma, but it is exactly the opposite with the lower respiratory tract infection
 
[27] 
. The most common causative organism associated with respiratory tract 
infection in the childhood period is Respiratory Syncytial Virus. RSV has been 
suspected of having unique effects on the infant respiratory tract favouring 
allergic sensitization and asthma
 [28]
.  The strongest correlate of wheezing before 
age 3 is small airway calibre, whereas wheezing after age 3 correlates with 
elevated serum IgE and a maternal history of asthma
 [29]
. 
OTHER MICROBIALS IN ASTHMA: 
   Chlamydia pneumoniae and Mycoplasma pneumoniae, causing atypical 
pneumonia, infect the airway epithelium and stimulate local inflammatory 
reactions
 [30]
. They may worsen asthma in those who have the disease or induce 
it in those with some predisposing condition. 
 Chronic infection with the above organisms has important association 
with chronic severe asthma in adults. Significant IgA antibody titre against C. 
pneumoniae was strongly associated with asthma severity
 [31]
 . Presence of IgG 
antibodies was associated with a fourfold greater rate of decline in FEV1 in 
another
 [32]
. 
OROFAECAL INFECTIONS AND ASTHMA: 
                  Infection with intestinal microbes namely the Toxoplasma gondii, 
Helicobacter pylori, hepatitis A during infancy and childhood were found to 
have a higher association with protection against the atopy as compared with 
infections with respiratory pathogens (measles virus, varicella zoster, HSV, 
CMV and mumps virus). The possible explanation is that following exposure to 
these organisms there is a immune deviation in the gut lymphoid tissue. This 
newer concept has questioned the hygiene hypothesis which states that day care 
centres are associated with higher respiratory tract infections and thus protection 
against atopy, but this concept suggests the oro faecal infection as the 
immunodeviation process of protection against atopy. 
                  The emerging evidence of the possible importance of gut 
commensals and of gastrointestinal exposure for the induction of tolerance to 
airborne allergens suggests a possible explanation for the rise in allergic 
diseases in westernized, developed societies
 [33]
. With fewer siblings and less 
time spent outdoors in play, the exposure of modern children to the microbial 
world may be insufficient for the inductive programming of healthy, balanced 
immune responsiveness. The theory also suggests a strategy for primary 
prevention of allergic disease. If the microbes responsible are harmless or if 
their products can be identified, simply adding them to food may reduce the risk 
of atopic disease. This approach is already being tested in a birth cohort trial of 
oral lactobacillus supplementation during the first 6 months of life 
[34]
. 
DIET AND ASTHMA: 
                  The role of dietary factors is controversial. Diets that lack 
vitamins(C and A) trace elements like magnesium, selenium, and omega-3 
polyunsaturated fats or the diets that have a high salt or omega-6 
polyunsaturated fatty acid are found to have an increased risk of developing 
asthma. Vitamin D deficiency may also predispose to the development of 
asthma. Obesity is also an independent risk factor for asthma, particularly in 
women
 [35]
. 
TOBACCO SMOKING AND ASTHMA: 
Tobacco smoking has been an important risk factor in development of 
asthma both in individuals with and without family history of asthma. Its effect 
has been described in both active smoking and passive smoking
 [36]
. Tobacco 
causes its effect more in the children when the mother gets exposed to passive/ 
active smoking in the antenatal period. Tobacco smoking acts as an initial insult 
to the mucosal defence which results in infections and alternate activation of the 
immune system (Th2 lymphocytes). But the major effect of tobacco smoking in 
asthma comes through the decline in pulmonary function and increases 
exacerbations in known asthmatics. 
Summing up the hypothesis and concepts detailed above the development 
of asthma in an individual is directly related to the history of atopy in the 
family. A number of factors act to modify the atopy and thus determine the 
phenotypic expression of the disorder. The factors which lead on to the 
expression and thus disease favouring are low/high birth weight, prematurity, 
maternal smoking during pregnancy, high intake of salt, pet ownership, obesity
.
 
AIR POLLUTION AND ASTHMA 
Air pollutants like sulphur dioxide, ozone, and petroleum particulates, 
may precipitate asthma symptoms, but their role as etiological agent of the 
disease is much less certain. The present evidence argues against role for air 
pollution in asthma, as asthma is no more prevalent in cities with high levels of 
air pollution. Indoor air pollution may be important and have been proven to be 
associated with asthma. They include exposure to nitrogen oxides from cooking 
stoves and exposure to passive cigarette smoke. There is evidence to suggest 
that maternal smoking is a risk factor for asthma. 
ALLERGENS 
Exposure to allergens particularly inhaled allergens has been found to be 
a risk factor in sensitization to allergy and asthma. Although this is true the 
other way is not true, that is stringent measures in controlling these allergens 
have not resulted in prevention of asthma in this individuals. Exposure to house 
mite has been one such example when such exposure occurs in the early 
childhood. Domestic exposure particularly to cats has been associated with 
allergic sensitization but if it occurs early in the life it may be of protective 
value through induction of tolerance. 
OCCUPATIONAL EXPOSURE AND ASTHMA: 
Occupational exposure to chemical agents and allergens has been 
considered to be one among the leading causes of asthma in young adults. Over 
two hundred chemicals have been listed to have been associated with the 
development of asthma. The important agents among these have been toluene 
diisocyanate and trimetallic anhydrate. They have been associated with allergic 
sensitation irrespective of the history of atopy. Exposure to animal allergens in 
the laboratory has also found significant association with allergic sensitization. 
Occupational asthma may be suspected when symptoms improve during 
weekends and holidays. 
GENETICS IN ASTHMA: 
Asthma is regarded as a "complex" disease. The disease results from 
gene—environment and/or gene—gene interactions. It is unknown still as to 
how many genes may be involved in asthma susceptibility and what will be the 
strength of their effects. One more possibility is that a large number of genes 
may have actually involved in a combination for the development of asthma 
population, but only a small subset of genes may actually result in disease in 
affected individuals. This possibility would be difficult to detect with any of the 
used statistical approaches to population genetics. 
Several genomic regions have been identified in linkage analyses of asthma: 
CHROMOSOMAL REGIONS   
1. 5q31–33[37] [38] [39] 
2. 11q [40] [41]   
3. 12q [42] [43] [44] [45]  
Of the loci linked to asthma, the 5q23–31 locus is of particular interest. 
Several studies have demonstrated that this region contains genes related not 
only to the diagnosis of asthma
 [37]
 but also to elevated plasma IgE levels
 [46] [47] 
[48]
 and bronchial hyperresponsiveness
[49] 
. Among the candidate genes in the 
5q23–31 region are the genes for IL-4, IL-13, IL-5, IL-9, the locus control 
region, and the genes encoding for CD14 and the beta2-adrenergic receptor 
(β2AR). Several investigators have demonstrated an integral role for many of 
these candidate genes in the pathogenesis of asthma, IgE production, and mucus 
hypersecretion
[50][51][52][53]
  
 
GENETIC VARIATION 
Naturally occurring genetic variants, sequence variants, and 
polymorphism are an important source of genetic diversity. These variants may 
come in the form of single nucleotide polymorphisms, repeats, insertions, or 
deletions. Genetic variants in key regulatory regions (i.e., promoter regions) or 
in the gene itself may alter the normal biologic function or regulation of the 
gene. Many sequence variants in asthma candidate genes have been studied and 
have been found to be associated with asthma or asthma-related phenotype
 [54] 
. 
In addition to polymorphisms, it is evident that patterns of genetic variants, 
termed haplotypes, within a given gene or across a genetic region may be 
associated with disease. Haplotypes in the β2AR gene have been shown to have 
a pharmacogenetic effect by influencing the response to bronchodilators among 
subjects with asthma.
[55]
  
The practical application of genetics to diagnosis and management may 
come through pharmacogenetics, that is, the identification of genetic markers 
predicting responsiveness to specific therapies. A study demonstrates that there 
are ethnic-specific differences in the response to albuterol.
 [56]
 Preliminary 
evidence suggests that beta2-adrenergic receptor mutation in the form of 
polymorphisms may affect the response to bronchodilator treatment using an 
inhaled beta-agonist. A prospective study suggests that regular use of albuterol 
may cause a decline in peak flow and an increase in exacerbations in patients 
homozygous for Arg/Arg, in contrast to Gly/Gly, at the amino acid 16 
position.
[57]
  
ASTHMA TRIGGERS: 
Several stimuli trigger airway narrowing, wheezing, and dyspnea in 
asthmatic patients.  
ALLERGENS 
Inhaled allergens are mostly associated with the triggering episodes. 
Among the notable allergens are the Dermatophagoides species, allergens from 
the pets like cats and from insects like cockroaches. These are considered to be 
perennial allergens causing symptoms throughout the year. Pollens are seasonal 
allergens associated mainly with allergic rhinitis but they may trigger severe 
asthma when disrupted in large amounts during thunderstorms (thunderstorm 
asthma) 
VIRAL INFECTIONS: 
Infections of the respiratory tract by viruses like corona virus, rhino virus 
and RSV may exacerbate asthma symptoms. 
 
 
PHARMACOLOGIC AGENTS: 
Non selective beta blockers increase the risk of exacerbation in asthma by 
increasing cholinergic bronchoconstriction 
ASPIRIN SENSITIVE ASTHMA: 
This occurs in patients with genetic predisposition for marked production 
of leukotrienes due to the genetic polymorphisms of the enzyme cys-leukotriene 
C synthase. It is associated with late onset asthma, perennial symptoms and 
nasal polyps. Happens following exposure to non selective COX inhibitors 
especially aspirin. 
EXERCISE: 
Exercise induced asthma occurs in children mostly. It is due to the 
hyperventilation induced increase in osmolality that imbibes fluid in the airway 
leading to airway obstruction. The symptoms start soon after exercise and 
settles spontaneously in 30 minutes.  
FOOD AND PHYSICAL FACTORS: 
Certain foods containing metabisulfite, a preservative, may trigger 
asthma. Also shell fish and nuts may trigger asthma as a part of generalised 
allergic reaction. Physical factors like cold and hyperventilation trigger asthma. 
HORMONAL FACTORS: 
Premenstrual worsening in women secondary to fall in progesterone 
levels, thyrotoxicosis and phaeochromocytoma may worsen asthma. 
GASRTROESOPHAGEAL REFLUX: 
Gastroesophageal reflux is common in asthma as it is increased by 
bronchodilators. Acid reflux might trigger reflex bronchoconstriction, it rarely 
causes asthma symptoms, and antireflux therapy fails to reduce asthma 
symptoms in most patients. 
STRESS 
Many asthmatics report worsening of symptoms with stress. 
Psychological factors can induce bronchoconstriction through cholinergic reflex 
pathways. Paradoxically, very severe stress such as bereavement usually does 
not worsen, and may even improve, asthma symptoms. 
The understanding of the pathology and the pathophysiology of asthma 
has given us the proper explanation for the transformation of asthma into a 
irreversible airway disease that almost behaves like COPD. The review of this 
literature is thus designed in a way to make the understanding of the 
pathophysiology better with a crisp and brief cover on the management of the 
disease. 
PATHOLOGY  
STRUCTURAL CHANGES IN THE AIRWAY  
Asthma in its stable form has been characterised by invasion of multiple 
inflammatory cells in to the airway wall. They along with their inflammatory 
mediators bring about the pathological consequences like subepithelial collagen 
deposit along with goblet cell and smooth muscle hyperplasia and angiogenesis 
leading in to the structural airway changes in asthma.  
EPITHELIAL CHANGES: 
Epithelial changes described in the pathological features of asthma are 
epithelial denudation and squamous metaplasia. Of these the debate has been 
over the inclusion of epithelial denudation as a pathological hallmark of asthma. 
But studies haven’t clearly distinguished whether it is due to the disease per se 
or due to the artefact created secondary to the sampling. 
Squamous metaplasia is a pathological feature of asthma when the 
epithelium remains to be intact
 [59] 
. Goblet cell hyperplasia or hypertrophy is a 
consistent feature seen in patients with fatal asthma.
 [60][61]
 Goblet cell 
hyperplasia is also seen in mild to moderate asthma 
[62]
 . This  results in a 
threefold  increase, in the amount of stored mucin in the airway epithelium,  
which was also associated with up regulation the epidermal growth factor 
receptor expression (whose activation results in mucin production).
[63]
 Increases 
in stored mucin render asthmatic subjects vulnerable to mucin hypersecretion 
during periods when mucin secretagogue levels rise (e.g., during asthma 
exacerbations).
[64]
  
EOSINOPHILIC INFLAMMATION:  
Increase in the number of activated eosinophils is the pathological 
hallmark of asthma in the submucosa and airway epithelium. 
[65] [66] [67] [68]
 The 
degree of eosinophilia is highly variable, and relatively few eosinophils were 
identifiable in the airway tissue in a subgroup of asthmatic subjects.
 [65] 
. 
Eosinophil numbers are often increased in the peripheral blood, but peripheral 
blood eosinophilia is not as sensitive an indicator of asthma as sputum 
eosinophilia.
[69] 
SUBEPITHELIAL CHANGES: 
Large amounts of type III and V collagens, along with fibronectin and 
tenascin are deposited beneath the airway epithelium in the bronchus of 
asthmatic patients 
[70] 
.  Myofibroblast that are increased in asthma have been 
the source of these proteins.
 [71]
  
The bronchial blood vessels increase in both number and size in asthma. 
[72]
  The vessels are prone to have large volumes which increase the mucosal 
swelling and narrow the airway lumen
 [73]
 . They are also characterised by 
vasodilation, vascular permiability, plasma extravasation, and airway mucosal 
edema.
 [74][75] 
  
There is a hypertrophy and hyperplasia of airway smooth muscles 
[76] [77]
. 
Airway cartilage shows degeneration and pericartilaginous fibrosis.
 [78] 
CHANGES IN AIRWAY MUCUS: 
Eosinophil  lysophospholipase a derivative of eosinophils has been 
implicated in the formation of Charcot-Leyden crystals .
[79][80] 
.  Sheded 
epithelial cells form the creola bodies.
 [81]
 Albumin and DNA,the nonmucin 
molecules, whose concentrations are increased in asthma,
[82][83]
 reflect abnormal 
bronchovascular permeability and increased cellular inflammation. The albumin 
concentrations in sputum in asthma could be important, especially when 
combined with changes in the mucin concentration.
 [84]
Mucin glycoproteins are 
the predominant proteins in sputum, and mucin concentrations are modestly 
increased in asthma as compared to normal individuals.
 [83]
  Large amounts of 
mucus accumulation leads to increased sputum production, cough and airway 
obstruction that may even  precipitate life threatening attacks in asthma
[85][86] 
. 
LARGE AIRWAY VERSUS SMALL AIRWAY PATHOLOGY  
Pathologic changes at different sites in the tracheobronchial tree in 
asthma are qualitatively similar irrespective of the airway size and calibre 
[87] 
. 
The degree of subepithelial fibrosis in proximal airways is representative of its 
thickness in distal airways. Eosinophilic inflammation extending into the 
alveolar septa in asthmatic subjects
 [88] 
, challenges the notion that asthma is a 
disease whose pathology is limited to the airway wall. Goblet cell metaplasia 
may be particularly important as the source of mucus that occludes many small 
airways because small noncartilaginous airways do not have submucosal glands. 
AIRWAY PATHOLOGY IN ALLERGIC AND NONALLERGIC 
ASTHMA 
The pathology of "extrinsic" (allergic) asthma and "intrinsic" 
(nonallergic) asthma (as judged by skin test reactivity and IgE levels) does not 
differ.
[89]
 Both forms of asthma are characterized by increases in eosinophils, 
mast cells, and CD4
+
 lymphocytes expressing cytokine profiles typical of the 
Th2 lymphocyte subgroup.
[90][91][92]
  
FATAL ASTHMA  
Extensive mucus plugging of the airways, high degree of airway wall 
thickening with smooth muscle and submucosal gland hypertrophy is typically 
found in autopsies of asthma fatalities and is considered a major cause of 
asphyxiation during a lethal attack
 [93]
 . The predominant cells in fatal asthma 
are eosinophils,
[94]
 but neutrophils may also predominate in those who die very 
quickly after the onset of a lethal attack.
[95][96]
  
 
RELATIONSHIP BETWEEN AIRWAY PATHOLOGY AND ASTHMA 
SEVERITY  
All of the characteristic findings of asthma are at least qualitatively 
similar in mild, moderate, and severe asthma, but inflammation and pathology is 
worse in more severe asthma. Higher eosinophil percentages in induced sputum 
from asthmatic subjects are associated with lower FEV1 and heightened 
sensitivity to methacholine.
[97][98]
. FEV1 is inversely associated with genetic 
expression levels of IL-5 and IL-13 in the airway mucosa.
 [99][100]
 . Higher 
neutrophil percentages are found in induced sputum in patients with more 
severe asthma, and airway neutrophilia is more strongly associated with lower 
values of FEV1 than with greater bronchial reactivity to methacholine.
[97]
  
The pathology of severe asthma shows that more severe disease is 
associated with increased numbers of airway smooth muscle cells and 
fibroblasts in the submucosa.
[101]
  
SPECIFICITY OF AIRWAY INFLAMMATION  
Chronic obstructive pulmonary disease (COPD), may have an element of 
eosinophilic inflammation but to a lesser degree than is found in asthma.
[102]
 
Similarly, modest increases in airway eosinophilia are found in subjects with 
allergic rhinitis without history of asthma.
[103]
 Smooth muscle hypertrophy is a 
feature of chronic bronchitis as well as of asthma.
[104] 
. Mononuclear cell 
infiltrates of the airway wall are characteristic of both asthma and chronic 
bronchitis, but the nature of the mononuclear cell infiltrate differs: in asthma the 
cells consist predominantly of CD4
+
 lymphocytes, whereas in chronic bronchitis 
they consist predominantly of CD8
+
 lymphocytes
 [105] 
. Also, subepithelial 
fibrosis can be observed in chronic bronchitis and in allergic rhinitis, but the 
degree is much lower than in asthma.
 [106]
   
PATHOPHYSIOLOGY  
ORIGIN AND EVOLUTION OF ASTHMA  
        Based on inflammation within the airways as a main component a 
hypothesis has been suggested to the natural course of asthma. The mast cell, 
eosinophil, CD4 lymphocyte and airway epithelial cell have been substrates of 
the inflammation in asthmatics. The most important of all is CD4 lymphocyte.  
Individuals who have a genetic susceptibility for atopy when exposed to 
specific risk factors in the early life will mount a specific inflammation 
consisting of Th2 lymphocytes in the airways. This is made possible by intra 
uterine programming of the fetus with a lesser exposure to infections in the 
childhood which selectively stimulates the naive Tcells to differentiate into the 
Th2 cells. With certain viral infections this airway inflammation goes in for 
exacerbation and thus airway remodelling and worsening of the lung function. 
  
Figure 3:Summary of current hypotheses for the evolution of asthma.
[107]
   
INFLAMMATORY MECHANISM OF ASTHMA:  
When an inhaled antigen is encountered by the antigen presenting cells it 
is first uptaken by these cells and then processed and presented to the naive T 
cells. These naive T cells differentiate into Th1 and Th2 cells based on the type 
of cytokines that act on them. IL-3,4,5,6,9,10,13 are the cytokines secreted by 
Th2 cells and thus brings about asthma expression.  
IMMUNE MECHANISMS:  
A number of cells, cytokines have been elucidated in the pathophysiology 
of asthma. Yet only a few have been critical in the development of asthma 
phenotype. The noteworthy are as follows, Dendritic Cells, Antigen 
Presentation, T Cells, Cytokines, Airway Epithelium, B Cells, Mast Cells, 
Basophils, and IgE , Eosinophils , Neutrophils and Macrophages. A brief 
description on these cells and cytokines has been mentioned below. 
DENDRITIC CELLS, ANTIGEN PRESENTING CELLS, TCELLS AND 
CYTOKINES 
    Airway dendritic cells are antigen-presenting, potent at initiating and 
sustaining airway inflammation. Their density in the airway will increase 
rapidly upon airway stimulation with allergen.
 [108]
 Dendritic cells express co 
stimulatory molecules that facilitate T-cell activation and differentiation.
 [109]
 
CD4
+
 T cells are the principal recipients of antigen presented by dendritic cells. 
Environmental lipopolysaccharide is important in initiating allergic lung 
disease.
[109]
 Dendritic cells secrete a number of mediators, which include IL-12, 
prostaglandin E2, and IL-10, which critically influence effector CD4
+
 T-cell 
development. 
The Th2 cells selectively accumulate in the lungs during allergic 
inflammation
[110]
. The cytokines that contribute to the asthma phenotype are   
IL-4 and IL-13.  IL-4 functions primarily as a growth or differentiation factor 
for Th2 cells and promotes IgE secretion by B cells and IL-13 may also promote 
IgE secretion in humans. IL-10 negatively regulates both Th1 and Th2 
cytokines and is critical for maintaining the normal tolerogenic airway immune 
state and down-regulating allergic airway inflammation.
 [111] 
  
ROLE OF THE AIRWAY EPITHELIUM  
Airway epithelial cell functions well beyond those of barrier protection, 
mucus secretion, and the mucociliary clearance necessary for host defence
 [112]
. 
The epithelium responds to inflammatory stimuli by synthesizing biologically 
active mediators that can moderate the airway inflammation. These mediators 
include cytokines and chemokines that can influence inflammatory cell 
trafficking and activation of arachidonic acid metabolites, endothelin-1, nitric 
oxide, and reactive oxygen species.
 [113]
  
              Air pollutants, respiratory viruses, aeroallergens, bacterial products, 
eosinophil and neutrophil granule products, and Th2 cytokines may activate 
epithelial cells directly or indirectly.
 [114]
.Goblet cells of the airway and gut also 
express a chloride channel (Gob-5) that is essential for mucus hypersecretion 
and airway hyper responsiveness.
 [115] 
 
B CELLS, MAST CELLS, BASOPHILS, AND IgE  
Type I hypersensitivity reactions are considered an important cause of 
acute asthma exacerbations and may contribute to chronic airway inflammation 
in asthma. In these reactions antigen cross-links IgE that are bound to receptors 
on mast cells or basophils. This activates the cells and thereby release a variety 
of products, including histamine, tryptase, chymase, leukotrienes, platelet-
activating factor, and various cytokines (IL-4, IL-5, TNFα) that in turn promote 
airway hyperresponsiveness, mucus overproduction, fibroblast activation, and 
neuropeptide degradation. IgE-mediated activation of mast cells and basophils, 
and IgE-facilitated antigen presentation to T cells are considered important 
mechanisms of the early-phase and late-phase responses to inhaled allergen
 [116]
. 
EOSINOPHILS  
Eosinophils secrete inflammatory mediators like granule proteins, 
proteolytic enzymes, lipid mediators, oxygen metabolites, and cytokines. These 
mediators directly or indirectly cause airway narrowing, airway hyper 
reactivity, and mucus hyper secretion. Eosinophil numbers increase 
dramatically in the airways of asthmatic subjects 4 to 24 hours following an 
aerosolized allergen challenge,
[117]
 and their appearance coincides with the 
development of late-phase asthmatic responses
[118]
 . Eosinophil numbers 
increase in airway secretions during asthma exacerbations induced by 
corticosteroid withdrawal
[119]
 . Eosinophils are prominent in secretions and in 
the airway wall in fatal cases of asthma. Airway eosinophilia coincides with 
asthma severity. The action of corticosteroids in asthma are hypothesized to 
result at least in part from the eosinophilopenic effects of these drugs.
[120]
  
 
NEUTROPHILS  
Neutrophil numbers are increased in secretions and biopsies in both acute 
severe asthma and chronic severe asthma
 [121]
 
Neutrophil elastase, cathepsin G, and proteinase 3 are secreted by 
neutrophils and are important mediators of goblet cell and submucosal gland 
cell degranulation.
[122]
 . Neutrophils may potentiate asthma, particularly acute 
exacerbations, by inducing mucin hypersecretion and possibly by increasing 
bronchovascular permeability. The abnormal accumulation of neutrophils in the 
airways during acute exacerbations may be mediated by IL-8 secretion from 
airway epithelial cells activated by virus or antigen exposure.
 [123]
  
MECHANISMS OF LEUKOCYTE RECRUITMENT TO AND EGRESSION 
FROM THE AIRWAY  
Selectins, expressed on leukocytes, bind to their ligands on endothelial 
cells to initiate tethering and rolling, which is the first step in endothelial 
transmigration. Tethering and rolling is followed by firm adhesion mediated by 
integrins. Chemotaxis is the final step in inflammatory cell recruitment. 
Egression of inflammatory cells, a step in the resolution of inflammation, 
involves establishment of appropriate chemokine gradients. Matrix 
metalloproteinases (MMPs) regulated chemokines allow egression of allergic 
inflammation, especially MMP2.
 [124]
  
MACROPHAGES  
Macrophages may be involved in both the induction and effector phases 
of immune responses in asthma. In the induction phase, macrophages function 
in several ways, including the uptake, processing, and presentation of antigens 
and the secretion of immunostimulatory hormones.
[125]
 In the effector phase, 
macrophages function as cytotoxic cells and also as effector cells capable of 
secreting a wide variety of pro-inflammatory mediators including cytokines, 
arachidonic acid metabolites, and proteases.
[126]
. Studies have demonstrated that 
the beneficial effects of corticosteroids in asthma may be mediated at least in 
part by down-regulation of alveolar macrophages.
[127]
  
Hypotheses have been proposed claiming failure of macrophage-
mediated T-cell regulation to be an important factor in T-cell proliferation and 
activation in asthma.
 [128]
  
Only those allergens that possess protease activity (example: pollen, 
fungi) are capable of inducing allergic lung disease. 
EFFECTS OF AIRWAY INFLAMMATION: 
 Epithelial damage and shedding (contributes to airway hyperresponse). 
 Subepithelial fibrosis (contributes to non elastic irreversible airways). 
 Smooth muscle hypertrophy causes narrow airway. 
 Angiogenesis, micro vascular leakage and mucosal edema. 
 Mucus hypersecretion and accumulation leading to exacerbations. 
 Bronchoconstriction secondary to cholinergic stimulation 
AIRWAY REMODELING  
Airway remodeling in asthma may have at least three distinct consequences. 
1. Even moderate increase in airway thickening will markedly increase the 
airway narrowing and worsens the scenario following smooth muscle 
contraction.
[130]
  
2. The airway wall thickening is the reason behind the persistent and 
irreversible airflow limitation in some patients with asthma.
[131]
  
3. Increased blood flow with hyperplasia of goblet cell causes increase in 
mucus secretion leading on to mucus plug formation and precipitation of 
exacerbation
132] 
 
Hyperpolarized helium-3 is a gaseous contrast agent that provides a new 
technique for magnetic resonance imaging in asthma.  Studies have shown 
that this method can detect methacholine-induced bronchoconstriction
[133]
 
and it may prove useful for assessing the effects of treatment on airway 
narrowing secondary to remodeling. 
 
PHYSIOLOGIC DISTURBANCES  
The functional disturbances are most clearly seen during severe attacks. 
All physiologic consequences derive from narrowing of the airways. There is 
diffuse narrowing of the whole trachea and bronchi but the maximum narrowing 
occurs in bronchi of diameter between 2 to 5 mm.
[134]
  
Tests of airway function are abnormal.  There are a following pattern of 
spirometric tests that are characteristic of airflow obstruction. 
1. Increased airway resistance and reduced Maximum expiratory flow rates. 
Maximal inspiratory flow is also reduced but less so. 
2. Narrowing of peripheral airways results in their premature closure at 
higher lung volumes, and increase in residual volumes
 [135]
.  
3. Increase in the functional residual capacity is due to i)the inability of the 
lungs to empty during the expiratory phase of the respiratory cycle 
because of the high resistance to expiratory flow
[136]  
ii)another is a 
sustained increase in the activity of inspiratory muscles even during 
expiration.
[137]
 
4. The adaptive advantages of breathing at higher lung volumes are 
increases in the circumferential traction—or "tethering" force—on 
intrapulmonary airways, tending to hold them open, and an increase in 
the elastic recoil of the lungs, increasing the driving pressure for 
expiration. These adaptive gains are partially offset by a decrease in lung 
elastic recoil in acute, severe asthma.
[138]
  
5. The increased resistive work due to narrowing of airways and the 
increased elastic work due to reduced lung compliance with high thoracic 
cage volume leads to increase in work of breathing. This increased work 
must be performed by muscles of breathing placed at a mechanical 
disadvantage by overinflation of the thorax.  
6. At high thoracic volumes, the diaphragm and intercostal muscles must 
function over a suboptimal range of their length-tension curve, and 
accessory muscles (e.g., the sternocleidomastoids) are brought into 
play.
[139]
 The increase in the work of breathing causes fatigue, and the 
inappropriateness of the length-tension relationship in the muscles of 
breathing is perceived as dyspnea. 
PHYSIOLOGICAL DISTURBANCES IN ACUTE SEVERE ASTHMA: 
The airway narrowing of asthma affects gas exchange. The severity of 
obstruction is not uniformly distributed. Shifts in pulmonary blood flow cannot 
completely compensate for the under ventilation of the regions of lung 
subtended by the most obstructed airways. The resulting mismatch of 
ventilation to perfusion widens the alveolar-arterial oxygen difference [(A - a) 
PO2], and arterial oxygen tension in patients with acute severe asthma typically 
ranges between 60 and 69 mm Hg.
[140]
 The hypocapnia is caused  by 
hyperventilation  done by stimulation of neural receptors supplied by afferent 
fibers in the vagus nerves. This increased respiratory drive is almost invariable 
in acute asthmatic attacks. An elevated or even normal arterial PCO2 is a sign of 
severe airflow obstruction where there is a mismatch between muscles of 
respiration and the respiratory centre 
[141] 
Alveolar ventilation falls suddenly with any worsening of airflow 
obstruction, any loss in muscle performance (as from fatigue), or any decline in 
respiratory drive (as from administration or a narcotic or sedative drug). This 
raises the Pco2 and inhibits the muscle performance and respiratory drive 
(carbon dioxide narcosis) which if left untreated leads to respiratory failure and 
death.
 [142]
 Hypercapnia indicates severe exacerbation, which requires aggressive 
treatment with bronchodilators and preparation for possible intubation and 
mechanical ventilation. 
Severe airflow obstruction usually improves quickly with treatment but 
resolves entirely much more slowly. When symptoms have resolved, FEV1 and 
residual volume still average 50% and 200% of normal, respectively. Even 
when wheezing has resolved and the physical examination is entirely normal, 
maximal expiratory flow is still markedly reduced, especially at mid and low 
lung volumes and residual volume remains increased. 
 
 
PULMONARY FUNCTION TESTING  
Pulmonary function testing can be done both clinically and mechanically. 
The gold standard method used in measuring the lung volumes is spirometry. 
CLINICAL METHODS: 
1) Duration of the expiratory phase heard on auscultating over the  trachea  -
>6 sec obstructive 
2) Single breath count test-normal  35-40 
3) Candle blowing test at 15 cm 
SPIROMETRY:  
          Spirometry is a simple test that measures various lung volumes with the 
active patient’s effort of breathing. It is performed using a machine called 
spirometer. There are two types of spirometer. Volume-displacement and flow 
sensing spirometers. Flow sensing spirometers have largely replaced volume 
displacement spirometers.  
Pulmonary function testing performed between attacks, or even after long 
periods of remission of asthmatic symptoms, usually shows characteristic 
changes. The easiest to detect are reductions in maximal expiratory flow. 
Calculation of peak flow variability(the difference between the AM and PM 
values divided by the mean of the two) can also be used for detecting abnormal 
airway lability, as an indirect measure of bronchial responsiveness
[143]
.  
The volume of air expired during the first second of a forced expiratory 
manoeuvre from total lung capacity (FEV1) is the best-standardized, most 
widely used test for airflow obstruction. An improvement in FEV1 of more 
than 12% and more than 200 ml after administration of a bronchodilator is a 
hallmark of asthma.
[144] 
Interpretation of the FEV1 requires simultaneous 
measurement of the forced vital capacity (FVC), the total volume exhaled from 
total lung capacity (TLC) to residual volume. Usually the reduction in FEV1 is 
more than the reduction in FVC, so the FEV1/FVC ratio is typically low in 
asthma. An exception is severe asthma, in which residual volume may be so 
increased that the reduction in FVC is proportional to the reduction in FEV1. 
Conversely, treatment may reverse narrowing of peripheral airways, allowing 
exhalation of a greater volume before airway closure occurs, so the 
improvement in FVC can be proportionately greater than the improvement in 
FEV1.  
An index derived from the FVC is the maximum mid expiratory flow, or 
the forced expiratory flow between 25% and 75% of the FVC (FEF25–75%), the 
mean rate of flow over the middle half of the vital capacity. Flow over this 
lower lung volume was thought to be more precise for small airway obstruction 
than  the FEV1,
[145]
 and a normal FEF25–75% value indeed makes asthma 
unlikely
[146]
 but not impossible.  
An alternative to measuring FVC is measurement of the volume of air 
expired over the initial 6 seconds of a forced expiratory maneuver, the FEV6 
[147]
. This manoeuvre is less demanding on patients and equipment and virtually 
never leads to misclassification of disease or disease severity based on the FVC.  
TABLE 1: COMPARISON OF RESPIRATORY PATHOLOGIES USING 
SPIROMETRIC RESULTS 
 OBSTRUCTIVE RESTRICTIVE MIXED 
FEV1                 OR 
NORMAL 
 
FVC            OR 
NORMAL 
  
FEV1/FVC                 OR 
NORMAL  
 
Although above table can be used easily to interpret the obstructive and 
restrictive pattern differentiating asthma and COPD among the obstructive 
diseases using spirometry has limitations. They are as follows: 
1. The absence of reversibility does not exclude asthma as the asthmatic 
person’s response can vary from time to time and at times airway calibre 
in asthmatic subjects is absolutely normal and as not capable of dramatic 
improvement. 
2. FEV1 may improve significantly after bronchodilator and a change of 
>12% and > 200 ml in FEV1 can occur in COPD 
[148]
. 
3. In long standing bronchial asthmatics the airway remodelling may cause 
irreversible airflow obstruction and thus mimic COPD in picture. 
4. In India there has not been a wide spread practice of establishing the 
diagnosis of new onset asthma using spirometry making it a diagnosis 
only on the grounds of history. 
Therefore those patients presenting after a long duration of disease treated as 
asthma have severe airflow impairment which mimic COPD failing to qualify 
for the reversibility of airflow limitation following bronchodilator. 
TESTS OF AIRWAY RESPONSIVENESS  
Airway responsiveness is assessed by delivering progressively increasing 
doses of a provocative stimulus until a chosen index of airway caliber changes 
by a fixed amount. The stimulus used is methacholine, delivered as a nebulized 
aerosol in doubling concentrations at 10-minute intervals until FEV1 falls by 
more than 20%. The provocative concentration causing a 20% fall is calculated 
by interpolation and is expressed as the PC20  
Airway hyperresponsiveness, defined as a PC20 of less than 8 mg/mL, is 
classically seen in asthma. But this may also be found in other disorders, such 
as COPD, cystic fibrosis, and allergic rhinitis. The degree of responsiveness 
roughly correlates with the severity of the asthma.
 [149]
 
These agents activate the mechanisms responsible for the bronchoconstriction 
caused by irritants inhaled in ordinary life. A promising "indirect" agent for use 
in clinical practice is mannitol, which acts locally as the airway mucosa as a 
hypertonic stimulus. It is prepared in capsules of increasing strength, so serially 
increasing doses can be easily delivered from a handheld device.
 [150] 
CLINICAL FEATURES  
HISTORY  
The cardinal symptoms of asthma are wheezing, chest tightness, and 
shortness of breath. These symptoms are often precipitated by exercise, 
exposure to allergens, or viral respiratory infections. Variability from day to day 
with symptoms worsening at night is almost characteristic. 
[151]
 Others report 
variations in symptoms over minutes, and a few even have sudden severe 
attacks after long periods without symptoms. 
COUGH VARIANT ASTHMA: 
This form of asthma has been recognized in which wheezing and chest 
tightness are absent, and exertional dyspnea or cough is the sole presenting 
symptom.
 [151]
 .As many as 30% to 50% of patients with chronic cough have 
unrecognized asthma. This variant of asthma is more common in children, but 
13% of cases of cough-variant asthma occur in adults over 50 years of age.
 [152]
  
The cough associated with asthma is typically non-productive, nocturnal, and 
chronic, sometimes persisting for several years. It is worsened by the same 
stimuli that worsen the classic symptoms of asthma: exercise, inhalation of cold 
air, allergen exposure, and upper respiratory infections.
 [153]
 Relief is often 
prompt after initiation of appropriate bronchodilator and anti-inflammatory 
therapy. 
FAMILY HISTORY: 
Family history suggestive of allergic rhinitis, atopic dermatitis, or eczema 
increases the likelihood of a diagnosis of asthma. 
HISTORY REGARDING SEVERITY: 
The symptoms described by people with asthma are often so 
characteristic that a strong likelihood of asthma can be established by the 
medical history alone. The next task is to obtain information about the 
condition's severity. The features of fatality prone asthma, include a history of 
two or more emergency department visits or a hospitalization for asthma in the 
past year, the need for intubation and mechanical ventilation for any previous 
attack, a history of extremely rapid progression of symptoms,
 [154]
 and a history 
of anaphylactic sensitivity to certain foods, such as nuts or shrimp. For all 
patients with asthma, especially for those with adult onset asthma and nasal 
polyps, specific questions should be asked about the effects of ingesting aspirin 
or foods likely to contain sulphites (dried fruits, restaurant salads, some wines 
and beers). Both aspirin and sulphite ingestion can provoke severe, life-
threatening attacks in patients who otherwise have features of mild or moderate 
asthma.
[155]
  
Information about exposures to agents known to worsen asthma in the 
home or workplace, such as pets, cockroaches, house dust mites, and 
environmental tobacco smoke must be obtained. Questions should be directed 
toward conditions that complicate or aggravate asthma, such as allergic rhinitis, 
chronic sinusitis, or gastroesophageal reflux. 
PHYSICAL EXAMINATION: 
The most characteristic finding of asthma is polyphonic expiratory 
wheezing, thought to reflect turbulence of airflow in peripheral airways. 
Wheezing is the first physical finding detected as airflow obstruction 
progresses, but its absence does not indicate the absence of airflow obstruction.
 
As a reflection of turbulence of airflow, wheeze requires respiratory effort. 
Wheezing may thus be faint or inaudible in patients making little effort to move 
air. At the other extreme, the wheeze produced with rapid, forced exhalation 
does not correlate with airflow obstruction or with bronchial hyper 
responsiveness.
 [156]
  
The other physical findings of asthma are also reflections of airflow 
obstruction. Over inflation of the thoracic cage may be obvious, resulting in part 
from the air trapping caused by narrowing of peripheral airways and in part 
from the adaptive response of breathing at high lung volumes where lung recoil 
and airway calibre are greatest. 
Examination of nonthoracic organs often provides important diagnostic 
information. Swelling and pallor of the nasal mucosa suggest allergic rhinitis. 
Nasal polyps, especially in a patient with adult-onset asthma, suggest an 
increased risk of aspirin sensitivity.
 [157]
  
LABORATORY STUDIES  
1. Widespread but reversible narrowing of the airways. 
2. Increased bronchial responsiveness to inhaled stimuli.  
Obstructive pattern demonstrated in spirometry with FEV1 reversibility is 
almost suggestive of asthma. Reduction in maximal expiratory flow is a 
nonspecific finding.  
Measurement of bronchial responsiveness presents several advantages as a 
diagnostic test. Bronchial hyper responsiveness is nearly ubiquitous in patients 
with asthma, and its degree correlates with the severity of the disease. It is thus 
highly sensitive; the absence of bronchial hyper responsiveness should stimulate 
close re-examination of the grounds for suspecting asthma and consideration of 
other possible diagnoses. Its major disadvantage is that it is nonspecific. 
Bronchial hyper responsiveness is found in some patients with chronic 
obstructive bronchitis and allergic rhinitis. 
Chest X-ray may show over inflation of the lungs, bronchial wall thickening, 
and mucus plugs. 
Elevation in serum IgE levels, positive skin prick tests to common antigens, 
and blood eosinophilia demonstrate the atopic diathesis associated with asthma
 
but do not confirm the diagnosis of asthma.  
The association of eosinophilia, high serum levels of IgE, and changing 
pulmonary infiltrates in a patient with recurrent asthma, especially asthma 
associated with cough productive of plugs of mucus, should raise suspicion of 
allergic bronchopulmonary mycosis.
 [158]
  
Induced sputum from asthmatics contains a higher percentage of eosinophils 
and higher concentrations of eosinophilic cationic protein than do samples from 
healthy subjects. 
  Measurement of exhaled NO (eNO) is promising for diagnosis and 
treatment is easy to measure in children; and in children with asthma, eNO 
correlates with eosinophilic inflammation and airway responsiveness.
[159] 
 
TABLE 2 :DIFFERENTIAL DIAGNOSIS  
Category Examples 
Diseases causing 
recurrent episodic 
dyspnea 
Chronic obstructive pulmonary disease, coronary artery 
disease, congestive heart failure, pulmonary emboli, 
recurrent gastroesophageal reflux with aspiration, recurrent 
anaphylaxis, systemic mastocytosis, carcinoid syndrome 
Common diseases 
causing cough 
Rhinitis, sinusitis, otitis, bronchitis (chronic or postviral), 
bronchiectasis, cystic fibrosis, pneumonia, diffuse 
pulmonary fibrosis 
Common diseases 
causing airflow 
obstruction 
Chronic obstructive bronchitis and emphysema, 
bronchiolitis obliterans, cystic fibrosis, organic or 
functional laryngeal narrowing, extrinsic or intrinsic 
narrowing of trachea or major bronchus. 
  
Distinguishing asthma from chronic obstructive bronchitis has been 
made  difficult by the recognition that unremitting airflow obstruction may 
develop in patients with asthma,
[160]
especially in those who smoke.
[161]
 For 
individual patients, the important question is whether the airflow obstruction is 
likely to reverse with therapy. Reversibility is best determined directly, with 
a trial of corticosteroid and bronchodilator therapy.
[162]
  
ASTHMA SEVERITY 
Clinically asthma has been classified to categorise the patient’s severity at 
the time of diagnosis and for further follow up during therapy.
 [163] 
TABLE 3 : CLASSIFICATION OF ASTHMA SEVERITY
 
 intermittent Mild 
persistent 
Moderate 
persistent 
Severe 
persistent 
Daytime 
symptoms 
< 2/week >2/week not 
daily 
daily  Continuous  
Night time 
symptoms 
<2/month 3-4/month >1/week Nightly  
Activity 
limitations 
none  minor some extreme 
Reliever 
medications 
< 2/week >2/week not 
daily 
daily frequent 
FEV1orPEF >80% >80% 60-80% <60% 
Exacerbations  0-1/year >2/year >2/year >2/year 
Presence of just one of the feature will place the individual in the grade. The 
individual is also placed in the highest grade satisfied by him. 
SPECIAL FORMS OF ASTHMA 
This includes steroid dependent and resistant asthma, difficult asthma, 
aspirin sensitive asthma and exercise induced asthma. Aspirin and exercise 
related asthma have been discussed previously. 
 
STEROID-DEPENDENT ASTHMA 
This category includes patients who require continuous or frequent 
treatment with an oral glucocorticoid. The patients who continue to do poorly 
despite expert management may include those with steroid-resistant asthma, as 
defined by the failure of 2 weeks of treatment with 40 mg methylprednisolone 
to cause 15% improvement in FEV1.
[164]      
 
 SEVERE ASTHMA 
[165] 
This classification includes asthma prone to recurrent sudden attacks, or 
brittle asthma, as well as asthma that rarely cause severe exacerbations but that 
regularly interferes with sleep, exercise tolerance, or the ability to work, study, 
or play. Ratings of asthma severity are often based on responsiveness to 
treatment, rather than on any feature inherent to the disease. Most asthma is 
well controlled by low doses of an inhaled corticosteroid, and in clinical 
practice difficult-to-treat asthma (i.e., poorly controlled by inhaled 
corticosteroid therapy) is considered severe. Possible distinguishing features of 
this group are neutrophilic (in contrast to eosinophilic) inflammation of the 
airway mucosa,
 [166]
 greater preponderance of females, aspirin sensitivity, and 
lower level of atopy.
 [167]
  
 
 
ASTHMATIC BRONCHITIS 
The term, asthmatic bronchitis is used in two senses. One sense refers to 
the coincidence of asthma and chronic obstructive bronchitis in a cigarette 
smoker. Again, there are no formal criteria for this subcategory of asthma, but 
the usual features are recurrent dyspnea and wheezing, chronic productive 
cough, and airflow obstruction that are partially, but not completely, reversible 
with treatment. Overlap between asthma and chronic obstructive disease is 
common. The Dutch hypothesis has even proposed that the mechanisms 
responsible for asthma predispose to the development of COPD,
 [169]
 and the rate 
of decline in FEV1 is indeed faster in smoking asthmatics than in nonsmoking 
asthmatics or in healthy smokers.
 [170]
 The other sense of asthmatic bronchitis 
refers to episodes of prolonged production of cough and sputum purulence that 
often follow viral respiratory infections in asthmatic patients. 
ACUTE SEVERE ASTHMA 
         This is a life threatening condition in asthma. It is characterised by sudden 
worsening of the patient condition and severe breathlessness that does not 
resolve on regular doses of short acting inhaled bronchodilators. Acute severe 
asthma has been classified into 3 categories by the Global Initiative for Asthma. 
This classification has been used for managing the acute severe asthma. 
    
TABLE 4 : CLASSIFICATION OF ASTHMA EXACERBATION 
SEVERITY 
 Moderate 
 
Severe 
 
Impending 
Respiratory 
Arrest 
FEV1 or PEF 
predicted or 
personal best 
40-69% 
 
<40% 
 
25% or unable to 
measure 
 
Symptoms 
 
Dyspnea with 
talking 
Dyspnea at rest 
 
Severe dyspnea 
 
Exam Expiratory 
wheeze 
Inspiratory and 
expiratory 
wheeze 
Wheeze may 
become absent 
 Some accessory 
muscle use 
Accessory muscle 
use 
Chest retraction 
Accessory muscle 
use with 
paradoxical 
diaphragmatic 
movement 
  Agitation or 
confusion 
Depressed mental 
status 
Vitals RR < 28/min RR > 28/min 
 
Same as severe 
but could develop 
respiratory 
depression and/or 
bradycardia 
 HR < 110 HR > 110 
 
 
 O2sat > 91% 
 
O2sat < 91% 
 
 
 No pulsus 
paradoxus 
Pulsus paradoxus 
> 25 mm Hg 
 
PaCO2 Normal to 
hypocapnic 
>42 mm Hg 
 
Hypercapnea is a 
late sign 
 
MANAGEMENT  
PHARMACOLOGIC THERAPY  
FIGURE 4: CLASSIFICATION OF ASTHMATIC MEDICATIONS 
                                    MEDICATIONS FOR ASTHMA 
 
 
        SHORT TERM RELEIVERS                LONG TERM  CONTROLLERS 
               Beta 2 agonists                               oral/inhaled corticosteroids 
            Anti cholinergics                                Leukotriene antagonists                                                                                                               
            Methyl xanthines                                  mast cell stabilisers 
 
 RELAXES AIRWAY SMOOTH MUSCLE         ANTIINFLAMMATORY 
                                                                                       ACTION 
FIGURE 5 : DIAGRAM OF INHALER 
 
 
 
FIGURE 6 :TREATMENT ALGORITHM FOR ASTHMA 
EXACERBATION 
 
 
 
 TABLE 5 : STEPWISE APPROACH  IN ASTHMA MANAGEMENT 
Step 1 Mild, 
Intermittent 
Step 2 Mild, 
Persistent 
Step 3 Moderate, 
Persistent 
Step 4 Severe, 
Persistent 
Quick relief       
Short-acting 
inhaled β2-
agonist as needed 
for symptoms 
Short-acting 
inhaled β2-agonist 
as needed for 
symptoms 
Short-acting 
inhaled β2-agonist 
as needed for 
symptoms 
Short-acting inhaled 
β2-agonist as needed 
for symptoms 
Long-Term 
Control 
      
Daily 
medications not 
necessary 
Daily 
medications: 
Daily 
medications: 
Daily medications: 
    Low dose ICS 
  Low- to 
medium-dose 
ICS + LABA 
High-dose ICS + 
LABA 
  or or   
  
Cromolyn, 
nedocromil 
Medium-dose 
ICS 
Plus, if needed: 
systemic 
corticosteroids 
  or or   
  Theophylline 
Low- to medium-
dose ICS + 
sustained-release 
theophylline 
Addition of a third 
controller medication 
has not been 
adequately studied 
  or or   
  
Leukotriene 
inhibitors 
Low- to medium-
dose ICS + 
leukotriene 
modifier 
  
 
 
 
IS BRONCHIAL ASTHMA A FORERUNNER OF COPD? 
             By definition asthma is a reversible airway obstruction and COPD is 
irreversible airway obstruction involving the airway mucosal inflammation. 
Although there are other investigational differences like the predominant cells 
in the airway mucosa (CD8 lymphocytes in COPD and eosinophils in asthma), 
the size of airways involved (small airways in COPD and medium sized bronchi 
in asthma),parenchymal destruction(in COPD) , they do not make up much for 
the clinical use. Therefore by and large the reversibility of the airway 
obstruction has been the clinical modality of differentiating COPD and 
bronchial asthma. But during the natural course of asthma the inflammatory 
process causes airway remodelling, reduced response to beta agonists by 
alteration of  beta agonist receptors, thus leading on to a persistent airflow 
obstruction that does not respond to the therapies.  
                   Both in the COPD and asthma the predominance of neutrophils are 
seen at the time of exacerbations and thus this inflammatory cell has been 
postulated for the development of the irreversibility of the airflow obstruction in 
these patients.  During an exacerbation the mucus hyper secretion and reduced 
mucus clearance will cause accumulation of mucus plugs in the smaller airway 
and thus propagating small airway inflammation 
[177]
 in them. This has been 
attributed to the progression of the disease into irreversible state. As the number 
of exacerbations/ year increase the inflammatory process hastens up and leads 
to a faster remodelling of the airways and progresses to irreversibility. 
                Studies have pointed certain factors that are operational in bringing 
about irreversible airflow limitation in asthma. They are the duration of 
asthma
[172]
, Male sex, nasal polyps, asthma severity
[173]
, age of onset of 
asthma
[174]
, number of exacerbations a year
[175]
,sputum eosinophilia. 
                 All the above factors bring about the progression of asthma into a 
irreversible airway disease and thus transforming it into COPD
[176]
.  
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                                       AIM OF THE STUDY 
 
 To study the prevalence of irreversible air flow obstruction in 
chronic asthmatics using spirometry. 
  
 To assess the risk factors contributing to the development of 
irreversible airflow obstruction in chronic asthmatics.  
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                             METHODS AND MATERIALS 
           This study was planned to find out the prevalence of a certain objective 
in a particular population. The study design used is descriptive study. The study 
was started after obtaining the approval from the ethical committee.  
           The study was conducted in Government Royapettah Hospital in the 
department of Internal Medicine between April and October 2013. The target 
study population was planned as fifty cases.The study was conducted after 
formal informed consent from the patients. 
INCLUSION CRITERIA: 
Patients who were aged more than 18years with a asthma duration >10 years. 
EXCLUSION CRITERIA: 
• Active respiratory tract infection 
• Patients with active or old history of tuberculosis  
• Patients treated as COPD  
• Asthmatic patients who met hospitalization criteria.  
• Patient with complaints of hemoptysis  
• Recent MI (1 month)  
• Recent stroke, eye surgery, thoracic/abdominal surgery  
• Recent pneumothorax  
• Uncontrolled hypertension  
•  Active gastric ulcer/UGI bleeding  
•  Patients who are hemodynamically unstable.  
• Patients who have a smoking history starting before/concurrent with the 
onset of symptoms (breathlessness). 
STUDY PROTOCOL: 
              The patients attending the asthma clinic and the medicine op for 
medications were enrolled into the study. After a proper history and physical 
examination patients who had exclusion criteria were screened. The patients 
who met the inclusion criteria were advised a complete blood count, chest x-ray, 
ECG, Sputum analysis. Those patients who had no evidence of respiratory tract 
infection evidenced by the sputum result and ECG showing no evidence of 
acute ischemic/ recent infarction changes were chosen for the study. 
The patients had their disease defined as asthma by an affirmative answer to the 
following questions. 
• Diurnal variation of symptoms 
• Predominantly nocturnal symptoms 
• Seasonal aggravation of symptoms 
• Presence of nasal polyps 
• Allergic tendencies to known allergens 
• Positive family history 
• Complete relief of the symptom in the past/present with nebulisation  
• Normal or near normal activities in between the symptoms.  
         Those patients categorised as asthmatics were asked to refrain from 
smoking, coffee, tea and heavy physical activity immediately before the 
performance of pulmonary function testing (PFT) using spirometer. The patients 
were also asked to review after complete cessation of intake of salbutamol, 
theophylline for more than 48 hrs.  
         The patients were demonstrated how to perform PFT using spirometer. 
Flow sensing electronic spirometer which was accurately calibrated was used in 
this study. A total of 3 readings were taken both before and after bronchodilator 
nebulisation. Among the three, the well performed reading and the reading with 
the maximum values was considered.  
        The cases which demonstrated purely an obstructive pattern in the PFT 
were analysed for the reversibility of the obstruction. The cases who 
demonstrated a rise of FEV1% >12% or 200 ml following salbutamol 
nebulisation for 20 minutes were considered to have a reversible airflow 
obstruction. Those who failed to raise their values to above levels were given a 
trail of 40 mg of prednisolone for two weeks. PFT was performed two weeks 
later. Those who still did not achieve the above target values were considered to 
have a irreversible airflow obstruction. 
FEV1 reversibility=  postbronchodilator FEV1 - prebronchodilator FEV1 * 100 
                                                        prebronchodilator FEV1   
         The patients were initially divided into two groups. Those whose 
symptoms started <12 years where termed as childhood asthmatics and those 
who symptoms started >20 years were termed as late onset asthmatics. 
The results were tabulated and the prevalence rate of irreversible airflow 
obstruction among the 50 asthmatic cases was calculated. The distribution of 
cases between the childhood and late onset asthma was calculated. 
        Along with this other variables collected were duration of asthma, 
smoking, use of glucocorticoids, asthma severity, number of exacerbations/year. 
The number of exacerbations a year was defined by number of hospitalisations 
required for the symptoms which did not respond to conventional nebulisation. 
Measurement of smoking used in this study is smoking index which is defined 
as the number of cigarettes/ beedis per day multiplied by number of years of 
smoking. 
       An attempt was made to find out the association of above variables with 
irreversible airflow obstruction and their statistical significance was calculated 
using pearson’s chi-square tests. The significance of the association was 
established using the p value. 
 If the P value is  0.000 to 0.010 it is highly significant. 
 If the P value is 0.011 to 0.050 it is significant. 
 If the P value is 0.051 to 1.000 it is not significant. 
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                                            RESULTS 
                       A total of 66 people took part in the study out of which 7 people 
were excluded as there was an overlap between the age at onset of symptoms 
and age at which they started to smoke. 9 people did not come for follow up 
after two weeks steroid trail. Final population under the study was 50. 
FIGURE 6: POPULATION UNDER STUDY 
                                                                 
 
 
DESCRIPTIVE STATISTICS: 
 Of the total population who were involved in the study 30 were males (60%) 
and 20 were females (20%) 
 
66 cases 
16 cases 
7 cases excluded 
9 cases lost 
follow up 
50 cases 
50 cases-total 
study population 
    TABLE 6: GENDER WISE DISTRIBUTION OF POPULATION 
 Frequency Percent 
Valid Male 30 60.0 
  Female 20 40.0 
  Total 50 100.0 
 
 
 
         The study population was distributed into 5 groups according to the 
duration of asthma symptoms. There were 13 people in the study had duration 
of 10-20 years (26%), 14 people had a duration of 20-30 years (28%), 14 people 
had a duration of 30-40 years (28%), 7 people had a duration of 40-50 years 
(14%) and 2 people had a duration > 50 years. 
60% 
40% 
chart 1 :distribution of gender 
males females 
  
        The population under study was classified into two groups. The first group 
with childhood onset of symptoms. This group had 30 patients. The other group 
had patients with onset of symptoms after the age of 20 years. This group had 
20 patients. 
 
10-20 years 20-30 years 30-40 years 40-50 years > 50 yrs 
chart 2: distribution of cases 
according to duration of illness 
13 14 14 7 2 
0 
2 
4 
6 
8 
10 
12 
14 
16 
n
u
m
b
e
r 
o
f 
ca
se
s 
chart 2: distribution of cases according to 
duration of illness 
chilhood asthma late onset asthma 
chart 3: classification based on 
age of onset of asthma 
30 20 
0 
5 
10 
15 
20 
25 
30 
35 
n
u
m
b
e
r 
o
f 
ca
se
s 
chart 3: distribution based on age of onset of 
asthma 
 Amongst the study group there were 13 cases (26%) with smoking history. All 
the cases were males.  
                                                     
 TABLE 7: SMOKERS 
 Frequency Percent 
Valid Yes 13 26.0 
  No 37 74.0 
  Total 50 100.0 
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Chart 4 : distribution of smokers in the study 
population 
        Use of steroid in the population was studied along with other variables. 27 
cases had a positive history of steroid use(both oral and inhaled form) which 
amounted to 54% of the study population and 23  cases had negative history for 
steroid use which amounted to 46% of the study population. 11 of  them were 
females and 16  of them were males. 
                                                    
 TABLE 8 :USE OF STEROID 
                                        Frequency Percent 
Valid Yes 27 54.0 
  No 23 46.0 
  Total 50 100.0 
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chart 5 : steroid use in the study population 
YES NO 
  Improvement in fev1 >12% or 200ml in pulmonary function test following 
bronchodilator nebulisation and oral steroids-steroid trail (for those who did not 
show improvement after bronchodilator nebulisation) characterised the 
reversibility of airway obstruction. The population was categorised into two 
groups with this outcome.  Cases with reversible airflow obstruction (25 
patients) and those with irreversible airflow obstruction (25 patients). 
                               
 TABLE 9: REVERSIBILITY OF AIRFLOW LIMITATION 
 Frequency Percent 
Valid Yes 25 50.0 
  No 25 50.0 
  Total 50 100.0 
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chart 6: distribution according to  airflow 
limitation 
  The above value suggested that 50% of the population under study who had 
bronchial asthma had irreversible air flow obstruction. Thus a high prevalence 
of irreversible airflow limitation was noted among asthmatics. 
 
Asthma severity was classified according to the guidelines proposed by GINA. 
It was divided into 4 groups. 1) Intermittent 2) mild persistent 3) moderate 
persistent 4) severe persistent. There were 5,6, 21and 18 cases in intermittent, 
mild persistent, moderate persistent and severe persistent groups respectively. 
TABLE 10:ASTHMA SEVERITY 
 Frequency Percent 
Valid Intermittent 5 10.0 
  Mild 6 12.0 
  Moderate 21 42.0 
  Severe 18 36.0 
  Total 50 100.0 
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chart 7: severity of asthma 
RESULTS OF ANALYSIS: 
With the above data a comparison was made between the variables and the 
reversibility of airflow limitation in the cases and an attempt made to bring out 
the correlation between those variables and the reversibility of airflow 
limitation.  The variables considered were age of onset, duration  of asthma, 
smoking  history , steroid usage, number of exacerbations of symptoms/year 
and severity of asthma. 
AGE OF ONSET : 
A correlation between age at onset of asthma and air flow limitation was 
plotted. The results are as follows. 
TABLE 11: age at onset of asthma and airflow limitation 
   Age at Onset of Asthma Total 
    Late onset Childhood   
Reversibility of 
Airflow Obstruction 
Yes Count 
9 16 25 
    % within Reversibility of Airflow 
Obstruction 
36.0% 64.0% 100.0% 
    % within Age at Onset of Asthma 45.0% 53.3% 50.0% 
  No Count 11 14 25 
    % within Reversibility of Airflow 
Obstruction 
44.0% 56.0% 100.0% 
    % within Age at Onset of Asthma 55.0% 46.7% 50.0% 
Total Count 20 30 50 
  % within Reversibility of Airflow 
Obstruction 
40.0% 60.0% 100.0% 
  % within Age at Onset of Asthma 100.0% 100.0% 100.0% 
                                                 Chi-square tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square .333(b) 1 .564 
Continuity Correction(a) .083 1 .773 
Likelihood Ratio .334 1 .563 
Linear-by-Linear Association 
.327 1 .568 
No of Valid Cases 50     
 
A correlation between late onset asthma and irreversible airflow obstruction was 
sought. The values were statistically insignificant (p=.56(>.05)). But it was 
observed that the prevalence of irreversible airflow obstruction among the late 
onset asthma was greater (55%) than those with childhood onset asthma (46%). 
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chart 8 : comparison of airflow limitation and 
age of onset of asthma 
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DURATION OF ASTHMA: 
An association between the duration of asthma and airflow obstruction was 
sought. The results are as follows. 
TABLE 12: Duration of asthma and reversibility and airflow obstruction 
   
Reversibility of Airflow 
Obstruction Total 
    Yes No   
Duration of Asthma Below 20 Count 
10 3 13 
    % within Duration of Asthma 
76.9% 23.1% 100.0% 
    % within Reversibility of 
Airflow Obstruction 40.0% 12.0% 26.0% 
  20-30 Count 
11 3 14 
    % within Duration of Asthma 
78.6% 21.4% 100.0% 
    % within Reversibility of 
Airflow Obstruction 44.0% 12.0% 28.0% 
  30-40 Count 
4 10 14 
    % within Duration of Asthma 
28.6% 71.4% 100.0% 
    % within Reversibility of 
Airflow Obstruction 16.0% 40.0% 28.0% 
  40-50 Count 
0 7 7 
    % within Duration of Asthma 
.0% 100.0% 100.0% 
    % within Reversibility of 
Airflow Obstruction .0% 28.0% 14.0% 
  Above 50 Count 
0 2 2 
    % within Duration of Asthma 
.0% 100.0% 100.0% 
    % within Reversibility of 
Airflow Obstruction .0% 8.0% 4.0% 
Total Count 
25 25 50 
  % within Duration of Asthma 
50.0% 50.0% 100.0% 
  % within Reversibility of 
Airflow Obstruction 100.0% 100.0% 100.0% 
  
                                                  
 
                                                       Chi-square tests 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 19.912(a) 4 .001 
Likelihood Ratio 23.970 4 .000 
Linear-by-Linear Association 16.629 1 .000 
N of Valid Cases 
50     
 
There was a strong association established between the duration of asthma and 
the reversibility of airflow limitation. The patients with longer duration had 
irreversible airflow obstruction. This was statistically significant p value 
.001(highly significant). 
 
There was a difference in the time period for the occurrence of irreversible 
airflow obstruction amongst the late onset and child hood onset asthma. 
10-20 years 20-30 years 30-40 years 40-50 years >50 years 
reversible 10 11 4 0 0 
irreversible 3 3 10 7 2 
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Chart 9: comparison between duration of asthma and 
airflow limitation 
 Those within late onset group had irreversible airflow limitation as early 
as 16 yrs (10-20 years interval) and those with childhood asthma had 
irreversible airflow limitation around 33years (30-40 years interval). 
 
Smoking and use of steroid were seen as factors which were distributed 
throughout this distribution. Even though the data suggests that irreversible air 
flow obstruction is seen as early as 16 years the influence of steroids and 
smoking was seen in the groups 10-20 years and 20-30 years. Duration >30 
years was undisputedly associated with irreversible airflow limitation 
irrespective of the smoking and steroid use in late onset asthma group. Similarly 
Duration >40 years was undisputedly associated with irreversible airflow 
limitation in the childhood onset asthma group. Thus late onset asthma has 
been found to have a relatively earlier onset of irreversible obstruction 
than childhood onset asthma. 
 
Mean ages of the study population under the reversible airway obstruction and 
irreversible airway obstruction were 34 and 54 years respectively 
TABLE 13 : Mean ages of study population 
 
Reversibility of 
Airflow Obstruction N Mean Std. Deviation 
Std. Error 
Mean 
Age in years Yes 25 34.96 8.653 1.731 
No 25 53.64 9.945 1.989 
 
SMOKING: 
Smoking was prevalent only in the male gender in this study. An association 
between the reversibility of airflow obstruction and smoking was matched.  
TABLE 14 : Smoking and reversibility of airflow obstruction 
   Reversibility of Airflow Obstruction Total 
    Yes No   
Smoker Yes Count 3 10 13 
    % within Smoker 23.1% 76.9% 100.0% 
    % within Reversibility of Airflow 
Obstruction 
12.0% 40.0% 26.0% 
  No Count 22 15 37 
    % within Smoker 59.5% 40.5% 100.0% 
    % within Reversibility of Airflow 
Obstruction 
88.0% 60.0% 74.0% 
Total Count 25 25 50 
  % within Smoker 50.0% 50.0% 100.0% 
  % within Reversibility of Airflow 
Obstruction 
100.0% 100.0% 100.0% 
 
                                                Chi-square tests 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 5.094(b) 1 .024     
Continuity Correction(a) 3.742 1 .053     
Likelihood Ratio 5.309 1 .021     
Fisher's Exact Test       .051 .025 
Linear-by-Linear 
Association 
4.992 1 .025     
N of Valid Cases 50         
 
The above statistical data shows that prevalence of smoking in cases with 
irreversible airflow limitation was higher among chronic asthmatics. The p 
value is statistically significant (.02). 
 
Also a correlation was made between the smoking index and the reversibility of 
the airflow obstruction amongst the smokers. It was found that those with 
irreversible airflow obstruction had a smoking index more than 100. 
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chart 10 : comparison  between smoking and  
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USE OF CORTICOSTEROIDS:   
The study also witnessed many cases with steroid usage. The steroid use among 
the people varied. Both inhalational and oral corticosteroids were included as 
steroid intake. A correlation between steroid usage and its protective effect over 
the reversibility of airflow limitation was observed. The results are as follows. 
TABLE 15: steroid usage and irreversible airflow obstruction 
   
Reversibility of Airflow 
Obstruction Total 
    Yes No   
Use of Steroid Yes Count 15 12 27 
    % within Use of Steroid 55.6% 44.4% 100.0% 
    % within Reversibility of Airflow 
Obstruction 
60.0% 48.0% 54.0% 
  No Count 10 13 23 
    % within Use of Steroid 43.5% 56.5% 100.0% 
    % within Reversibility of Airflow 
Obstruction 
40.0% 52.0% 46.0% 
Total Count 25 25 50 
  % within Use of Steroid 50.0% 50.0% 100.0% 
  % within Reversibility of Airflow 
Obstruction 
100.0% 100.0% 100.0% 
                                                     Chi-square tests 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square .725(b) 1 .395     
Continuity Correction(a) .322 1 .570     
Likelihood Ratio .726 1 .394     
Fisher's Exact Test       .571 .285 
N of Valid Cases 50         
 It was observed that use of steroid was not statistically significant in prevention 
of irreversible airflow limitation in patients with asthma duration >10 years. The 
p value was .395(>.05) 
Although certain facts were observed 
 Amongst the male smokers with the asthma duration of 10-20 years in the 
late onset asthma group, (4 cases) one case was on steroid. 3 cases had 
irreversible airflow limitation and the case with steroid use had reversible 
airflow limitation.  
 As observed previously late onset asthma had irreversible airflow 
limitation one decade ahead (20-30 years) of the childhood asthma where 
it was observed in 30-40 years of asthma duration. But both these groups 
also had reversible pattern demonstrated in the above specified range of 
asthma duration. This reversible pattern observation was made only in 
non smokers with steroid usage. 
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chart 12 : correlation between use of steroid 
and airflow limitation 
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ASTHMA SEVERITY: 
Asthma severity among the cases was plotted. An association between 
reversibility of airflow limitation and severity of asthma was sought.   
TABLE 16 : Asthma severity and reversibility of airflow obstruction                
   
Reversibility of Airflow 
Obstruction Total 
    Yes No   
Asthma Severity Intermittent Count 5 0 5 
    % within Asthma Severity 100.0% .0% 100.0% 
    % within Reversibility of 
Airflow Obstruction 
20.0% .0% 10.0% 
  Mild Count 6 0 6 
    % within Asthma Severity 100.0% .0% 100.0% 
    % within Reversibility of 
Airflow Obstruction 
24.0% .0% 12.0% 
  Moderate Count 12 9 21 
    % within Asthma Severity 57.1% 42.9% 100.0% 
    % within Reversibility of 
Airflow Obstruction 
48.0% 36.0% 42.0% 
  Severe Count 2 16 18 
    % within Asthma Severity 11.1% 88.9% 100.0% 
    % within Reversibility of 
Airflow Obstruction 
8.0% 64.0% 36.0% 
Total Count 25 25 50 
  % within Asthma Severity 50.0% 50.0% 100.0% 
  % within Reversibility of 
Airflow Obstruction 
100.0% 100.0% 100.0% 
                                                       
 
 
                                                      Chi-square tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 22.317(a) 3 .000 
Likelihood Ratio 28.075 3 .000 
Linear-by-Linear Association 20.082 1 .000 
N of Valid Cases 
50     
 
It was found that irreversible airflow limitation was seen prevalently in two 
groups-moderately persistent and severe persistent. Among this severely 
persistent asthma was found to be more associated with irreversible airflow 
limitation. Irreversible airflow limitation was significantly associated with 
severe persistent asthma. The p value was< .001(highly significant). 
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chart 13: severity of asthma in airflow 
limitation 
NUMBER OF EXACERBATIONS/YEAR: 
An analysis was done to see the number of exacerbations/year in cases with the 
both reversible and irreversible airflow limitation and the results were tabulated. 
TABLE 17 : Number of exacerbations in asthmatics 
   
Reversibility of Airflow 
Obstruction 
Total Yes No 
No. of Exacerbations 
per year 
0 Count 
10 0 10 
% within No. of 
Exacerbations per 
year 
100.0% .0% 100.0% 
% within 
Reversibility of 
Airflow Obstruction 
40.0% .0% 20.0% 
1 Count 
8 0 8 
% within No. of 
Exacerbations per 
year 
100.0% .0% 100.0% 
% within 
Reversibility of 
Airflow Obstruction 
32.0% .0% 16.0% 
2 Count 
6 9 15 
% within No. of 
Exacerbations per 
year 
40.0% 60.0% 100.0% 
% within 
Reversibility of 
Airflow Obstruction 
24.0% 36.0% 30.0% 
3 Count 
1 10 11 
% within No. of 
Exacerbations per 
year 
9.1% 90.9% 100.0% 
% within 
Reversibility of 
Airflow Obstruction 
4.0% 40.0% 22.0% 
4 Count 
0 5 5 
% within No. of 
Exacerbations per 
year 
.0% 100.0% 100.0% 
% within 
Reversibility of 
Airflow Obstruction 
.0% 20.0% 10.0% 
5 Count 
0 1 1 
% within No. of 
Exacerbations per 
year 
.0% 100.0% 100.0% 
% within 
Reversibility of 
Airflow Obstruction 
.0% 4.0% 2.0% 
Total Count 
25 25 50 
% within No. of 
Exacerbations per 
year 
50.0% 50.0% 100.0% 
% within 
Reversibility of 
Airflow Obstruction 
100.0% 100.0% 100.0% 
                                                    Chi-square tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 31.964(a) 5 .000 
Likelihood Ratio 42.422 5 .000 
Linear-by-Linear Association 27.943 1 .000 
N of Valid Cases 
50     
 
It was found that cases with irreversible airflow limitation had increased 
number of exacerbations of the symptoms in a year. This was statistically 
significant –p value <.001. 
 
    
Also along with this a graph was plotted comparing the number of 
exacerbation/year and the severity of the asthma in the cases. 
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chart 14:distribution of number of 
exacerbations between cases with reversible 
and irreversible airflow limitation 
 PREVALENCE OF CHRONIC COUGH: 
The study also saw that only irreversible airflow limitation was associated with 
symptoms of chronic bronchitis .The value was statistically significant p-<.001 
TABLE 18: chronic cough among study population 
   Reversibility of Airflow Obstruction Total 
    Yes No   
Chronic Cough Yes Count 0 16 16 
    % within Chronic Cough .0% 100.0% 100.0% 
    % within Reversibility of 
Airflow Obstruction 
.0% 64.0% 32.0% 
  No Count 25 9 34 
    % within Chronic Cough 73.5% 26.5% 100.0% 
    % within Reversibility of 
Airflow Obstruction 
100.0% 36.0% 68.0% 
Total Count 25 25 50 
  % within Chronic Cough 50.0% 50.0% 100.0% 
  % within Reversibility of 
Airflow Obstruction 
100.0% 100.0% 100.0% 
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                                                       Chi-square tests 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 23.529(b) 1 .000     
Continuity Correction(a) 20.680 1 .000     
Likelihood Ratio 30.016 1 .000     
Fisher's Exact Test       .000 .000 
Linear-by-Linear 
Association 
23.059 1 .000     
N of Valid Cases 50         
 
 
It was found that cases with irreversible airway obstruction with the longer 
duration had the symptom of chronic cough mimicking chronic bronchitis 
compared to those with lesser duration of the disease. 
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chart 16: chronic cough in the study population  
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Reversibility 
of Airflow 
Obstruction     Chronic Cough Total 
    Yes No   
Yes Duration of 
Asthma 
Below 20 Count 
  10 10 
      % within Duration of 
Asthma 
  100.0% 100.0% 
      % within Chronic Cough   40.0% 40.0% 
    20-30 Count   11 11 
      % within Duration of 
Asthma 
  100.0% 100.0% 
      % within Chronic Cough   44.0% 44.0% 
    30-40 Count   4 4 
      % within Duration of 
Asthma 
  100.0% 100.0% 
      % within Chronic Cough   16.0% 16.0% 
  Total Count   25 25 
  % within Duration of 
Asthma 
  100.0% 100.0% 
  % within Chronic Cough   100.0% 100.0% 
No Duration of Asthma Below 20 Count 0 3 3 
      % within Duration of 
Asthma 
.0% 100.0% 100.0% 
      % within Chronic Cough .0% 33.3% 12.0% 
    20-30 Count 3 0 3 
      % within Duration of 
Asthma 
100.0% .0% 100.0% 
      % within Chronic Cough 18.8% .0% 12.0% 
    30-40 Count 4 6 10 
      % within Duration of 
Asthma 
40.0% 60.0% 100.0% 
      % within Chronic Cough 25.0% 66.7% 40.0% 
    40-50 Count 7 0 7 
      % within Duration of 
Asthma 
100.0% .0% 100.0% 
      % within Chronic Cough 43.8% .0% 28.0% 
    Above 50 Count 2 0 2 
      % within Duration of 
Asthma 
100.0% .0% 100.0% 
      % within Chronic Cough 12.5% .0% 8.0% 
  Total Count 16 9 25 
  % within Duration of 
Asthma 
64.0% 36.0% 100.0% 
  % within Chronic Cough 100.0% 100.0% 100.0% 
 
The data was statistically significant – p value .06. Therefore it is hypothesised 
that irreversible airflow obstruction with longer duration behaves clinically like 
a chronic obstructive lung disease. Chronic cough was defined as per the 
chronic bronchitis definition(>3months a year for two consecutive years). 
                                                          
                                                     Chi-square tests 
Reversibility of Airflow 
Obstruction   Value df 
Asymp. Sig. (2-
sided) 
Yes Pearson Chi-Square .(a)     
N of Valid Cases 25     
No Pearson Chi-Square 14.583(b) 4 .006 
  Likelihood Ratio 19.211 4 .001 
Linear-by-Linear Association 6.306 1 .012 
N of Valid Cases 25     
 
   
Irreversible air flow obstruction and its correlation  
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Asthma severity  
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                                            DISCUSSION 
                Years of medical school teaching and medical practice has believed 
Asthma to be a chronic inflammatory disease of the airways especially the 
medium sized bronchi that is characterised by variable and reversible airflow 
obstruction. But recently there are a lot of studies in the international forum that 
have challenged this view. Asthma has been seen as one of the forerunners of 
COPD, which is characterised by irreversibility of airflow obstruction. This 
study was conducted in the view to analyse the results of the newer studies 
which have shown irreversible airflow obstruction in asthmatics. 
                In our country a baseline Pulmonary Function Tests-PFT (using 
spirometer) was not practiced widespread in the past, when a case was first 
diagnosed as asthma. So this study has focussed much on patient’s history as the 
major tool for confirming the diagnosis of asthma in them. PFT here was used 
as a tool only to demonstrate the reversibility of airflow obstruction. In the PFT, 
values that were considered for this study were FEV1 (forced expiratory volume 
in first second),FVC(forced vital capacity or timed vital capacity), FEV1/FVC.  
                In this study it was found that 50% of the study population had a 
irreversibility of airway obstruction. Most of them were from the male gender 
(68%) amongst which a considerable number of smokers were present (26%). A 
gender wise significance could not be associated with the irreversibility of 
airway obstruction as the female gender in the study group lacked smokers 
which stood as a confounding factor.  
                Duration of asthma was found to be a single independent factor 
associated with the development of irreversible airflow obstruction in 
asthmatics in the study population. There are also supporting studies regarding 
this view. In a study published in the Eur Respir J 2004; 24: 122–128 by D. 
Bumbacea et al the parameters associated with the persistent airflow limitation 
in chronic severe asthma was analysed. It had proved that patients with severe 
form of the disease spectrum had a longer duration of the disease. The same 
study also suggested that use of steroid did not have any influence in the 
prevention of irreversibility in asthmatics. The similar results were obtained in 
our study with the use of steroid in the patients having an insignificant 
association with irreversible airflow obstruction in asthmatics. But the study 
found that those patients who had use of steroids still demonstrated reversibility 
of airflow limitation when compared to the cases that had similar duration of 
asthma. This sheds a view that although the use of steroid could not prevent the 
development of irreversible airflow obstruction it may prolong the duration of 
asthma with reversibility of the airflow limitation.  
                               Prevalence of smoking among the irreversible airflow 
obstruction was high and statistically significant. This is although suggestive of 
additive effect to the asthma in the development of irreversible airflow 
obstruction in asthmatics; it does not stand as an independent factor in the 
development of the irreversible airflow obstruction. Similar results were 
achieved in the  study published by Alan .L. James et al in his study published 
in the American Journal of Respiratory and critical care medicine Vol 171 2005. 
The study also saw that among the late onset asthmatics with duration of asthma 
<20 years smoking was detrimental in causing an irreversible pattern. Thus this 
study views smoking to have an additive effect in the disease pathology and 
also suggests that smoking has been associated with earlier onset of 
irreversibility of airflow limitation in asthmatics especially the late onset 
asthmatics.  
                The study population had two main groups. Late onset asthma and 
childhood onset asthma. The association of late onset asthma with severity of 
asthma and the poor lung function in the asthmatics was demonstrated by 
Baptist AP et al in the study published  J Asthma 2013 Oct;50(8):836-41. In this 
study the association of late onset asthma with the irreversible airflow 
obstruction was not statistically significant. But the prevalence of the 
irreversible pattern was more with (55%) with the late onset asthma than the 
childhood group (46%). 
                 Asthma severity was found to have a strong correlation with the 
irreversible airflow obstruction. Severe persistent asthma was seen to be highly 
prevalent (64%) among the irreversible airflow obstruction. This significant 
association is in accordance with the natural course of the asthma. Asthma over 
the years of progression leads to airway remodelling and thus leads to a decline 
of lung function and then leads to irreversible airflow obstruction. This decline 
in lung function manifests as severe persistent asthma. These patients had a 
longer duration of illness and thus a severe decline in the lung function. A 
similar consensus was reached in the study published in the Eur Respir J 2004; 
24: 122–128 by D. Bumbacea et al. Thus this study is of opinion that asthmatics 
with the longer duration of asthma had severe asthma and greater decline in 
lung function with irreversible airflow obstruction. 
Another parameter considered in the study was number of exacerbations/ year 
or the number of hospitalisations /year for the sudden increase in severity of 
symptoms.  The number of exacerbations/year was >2 in the study population 
with irreversible airflow obstruction as compared to those reversible pattern. 
Again this is in accordance with the natural history of asthma. The more the 
exacerbations more is the airway inflammation and more in the airway 
remodelling and more chance of irreversible airflow limitation. evidence to this 
is supported by the study published Matsunaga et al in Respir Med. 2013 
Mar;107(3):355-60.  
                Asthmatics with irreversible airflow obstruction satisfied the criteria of 
COPD in this study as per the PFT. A probe on the symptoms of these patients 
and a comparison of these patients with those with reversible airflow limitation 
was made. The patients with irreversible airflow obstruction saw a large 
proportion(64%) of patients with cough which was of productive nature and that 
lasted for more than 3 months  a year. This had a resemblance to chronic 
bronchitis. The cases in the reversible airflow limitation group did not satisfy 
this pattern of cough. Most of them if so had only a dry cough. This evidence 
also speaks in favour of asthma as a forerunner and independent risk factor for 
the development of COPD. A similar result was obtained in the study published 
by J M Vonk et al in his study published in the Thorax 2003;58:322–327. 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS OF THE STUDY 
        
1. This study was done in a small number of patients. Study in a larger 
population is needed. 
2. A previous Pulmonary Function Test showing reversible airflow 
obstruction suggestive of asthma  was not available with the participants 
who were enrolled as asthmatics in this study. 
3. The study concentrated history from the patient as a major source of the 
data and a considerable population was elderly. Therefore more of 
subjective than of objective data was used.  
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CONCLUSION 
                     Duration of asthma and asthma severity were independently 
associated with the development of irreversible airflow obstruction in 
asthmatics of >10 years duration. Smoking and lack of steroid played additive 
roles along with duration of asthma in the development of irreversible airflow 
obstruction. Age at onset did not find any significance in this study but further 
studied with larger population could bring out this association. With the 
development of irreversible obstruction these asthmatics behaved more like 
patients with COPD clinically ( although pathological evidence was not done to 
confirm this ) and thus it is evident that asthma is a indepent risk factor for 
COPD in a longer duration of course. This study helps us to recognise the risk 
factors associated with the acceleration of the disease process in asthmatics and 
thus helps us to take necessary steps like avoiding smoking, using inhaled 
corticosteroids for a better patient living. Also the study highlights the 
importance of Pulmonary Function Testing in monitoring the disease process. 
Finally the recognition of irreversibility of the airflow limitation is of immense 
importance for the management of these patients both in emergency rooms and 
in the daily practice schedules, failing this, leads to deleterious effect on the 
patient iatrogenically. 
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        PROFORMA 
 
           PATIENT INFORMATION SHEET 
                                          ASTHMA QUESTIONNAIRE 
 
NAME:                           AGE:             SEX:          OCCUPATION: 
Age of onset of symptoms: 
Breathlessness- i) duration            
                            ii) MMRC grading              
                            iii) relation of episodes- a)day time 
                                                                       b)night time 
                            iv) no.of. episodes requiring hospitalisation for the past 1 year 
                            v ) seasonal variation 
                            vi) early morning aggravation of symptoms 
                            
 Cough  –i) duration  
               ii) Nocturnal   
              iii) Seasonal variation 
              iv) dry or productive 
              v) Sputum 
              vi)  recent change in sputum consistency? 
Does strenuous activity brings out the symptom or aggravates it? 
Has nebulisation achieved complete recovery of symptoms in the past? 
Frequency of nebulisation 
Able to perform activities without limitation in between symptoms? 
h/o nasal polyps 
h/o aspirin intolerance 
h/o allergy 
family h/o asthma  
h/o tremors/palpitation 
h/o bone pain/fracture 
h/o oral thrush 
PRESENT MEDICATIONS: 
 
PERSONAL HABITS: 
 
COMORBID ILLNESS: 
 
 
                                                     GENERAL EXAMINATION 
Pallor:                               Icterus:                                       Cyanosis: 
Clubbing :                         Lymphadenopathy:                 JVP: 
Pulse rate:                        Blood pressure:                        SPO2: 
CVS:                                             P/A:                                         CNS: 
RS: 
 
INVESTIGATION 
1. CBC with ESR 
2. Chest X-ray 
 
3. ECG 
4. Sputum for AFB & gram stain  
5. Pulmonary function test 
  
Baseline value 
 
After salbutamol 
nebulization 
 
After 2 weeks oral 
prednisolone 
FEV1    
FVC    
FEV1/FVC    
 
 
 
 
ASTHMA SEVERITY: 
 
 
 
IMPRESSION: 
 
 
 
 
 
SIGNATURE OF INVESTIGATOR                                             SIGNATURE OF GUIDE  
 PATIENT CONSENT FORM 
 
STUDY DETAIL : 
STUDY CENTRE : 
PATIENT’S NAME  : 
PATIENT’S AGE : 
IDENTIFICATION NUMBER : 
 
                    I confirm that I have understood the purpose and procedure of the above study. I have 
the opportunity to ask questions and all my questions and doubts have been answered to my 
complete satisfaction. 
                    I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
                    I understand that the sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my permission to look at 
my health records, both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to this access. However I 
understand that my identity would not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
                    I hereby consent to participate in this study. 
        I hereby give permission to undergo complete clinical examination and diagnostic tests including 
haematological, biochemical, radiological tests. 
 
 
 
                                                                                                                               Signature/thumb impression: 
 
 
   
  
 
    
            
MASTERCHART 
 
 
 
 
 
 S.
N
O 
NAME 
A
GE 
SE
X 
OCCUP
ATION 
AGE 
AT 
ONSET 
OF 
ASTH
MA 
DUR
ATIO
N OF 
ASTH
MA 
REVERSI
BILITY 
OF 
AIRFLO
W 
OBSTRU
CYION 
SMO
KER 
SMOK
ING 
INDEX 
USE OF 
STEROI
D 
NO.OF 
EXACER
BATION
S/YEAR 
ASTHM
A 
SEVERIT
Y 
CHRONIC 
COUGH 
1 raziya bee 52 2 
house 
wife 
1 2 0 0 0 0 3 3 1 
2 lakshmi 46 2 
house 
wife 
1 2 1 0 0 1 2 3 0 
3 vimalammal 64 2 
house 
wife 
1 3 0 0 0 1 4 4 1 
4 
kurshid 
begum 
59 2 
house 
wife 
1 3 0 0 0 1 4 4 1 
5 rani 34 2 vendor 1 1 1 0 0 0 0 1 0 
6 kamala 36 2 maid 1 1 1 0 0 0 0 1 0 
7 fathima 38 2 
house 
wife 
1 1 1 0 0 1 0 2 0 
8 elumalai 35 1 
plumbe
r 
1 1 0 1 2 0 2 3 0 
9 imanullah 56 1 
buisene
ss 
1 2 0 0 0 1 4 4 1 
1
0 
david 44 1 
sanitary 
worker 
1 2 0 1 2 0 3 4 1 
1
1 
selvaraj 50 1 coolie 1 2 1 0 0 1 3 4 0 
1
2 
mani 38 1 barber 1 1 0 1 2 0 3 4 0 
1
3 
mohammed 33 1 
rice 
shop 
worker 
1 1 1 0 0 0 0 3 0 
1
4 
ravi 42 1 
auto 
driver 
1 1 1 1 1 1 0 2 0 
1
5 
raja 37 1 coolie 1 1 0 1 2 0 2 3 0 
1
6 
chittibabu 46 1 coolie 1 2 1 0 0 1 2 3 0 
1
7 
jaffer 36 1 
buisene
ss 
1 1 1 0 0 1 0 2 0 
1
8 
kandasamy 64 1 
watchm
an 
1 3 0 1 3 1 2 3 1 
1
9 
kesavan 72 1 teacher 1 4 0 1 2 1 5 4 1 
2
0 
sivalingam 68 1 
watchm
an 
1 3 0 0 0 1 3 3 1 
2 pushpa 22 2 student 2 1 1 0 0 1 1 1 0 
1 
2
2 
shanti 19 2 student 2 1 1 0 0 0 0 2 0 
2
3 
mary 28 2 
shop 
assistan
t 
2 2 1 0 0 1 0 2 0 
2
4 
radha 32 2 vendor 2 2 1 0 0 0 2 3 0 
2
5 
zuleika bee 30 2 
house 
wife 
2 2 1 0 0 0 2 3 0 
2
6 
eashwari 38 2 
shop 
assistan
t 
2 3 1 0 0 1 2 3 0 
2
7 
ismath 42 2 
house 
wife 
2 3 1 0 0 1 1 3 0 
2
8 
radhika 44 2 maid 2 3 0 0 0 0 3 4 0 
2
9 
sivagami 46 2 
house 
wife 
2 3 0 0 0 0 2 4 0 
3
0 
parvathy 52 2 
house 
wife 
2 4 0 0 0 1 2 3 1 
3
1 
rajarajeshw
ari 
56 2 
house 
wife 
2 4 0 0 0 1 2 4 1 
3
2 
rahamath 
nisha 
60 2 
house 
wife 
2 4 0 0 0 0 3 4 1 
3
3 
annie 64 2 
house 
wife 
2 5 0 0 0 1 2 3 1 
3
4 
raju 19 1 student 2 1 1 0 0 1 0 1 0 
3
5 
karthick 22 1 BPO 2 1 1 0 0 0 1 3 0 
3
6 
arokya raj 28 1 coolie 2 2 1 0 0 1 0 1 0 
3
7 
humayun 32 1 mason 2 2 1 0 0 0 1 3 0 
3
8 
saamy 34 1 
buisene
ss 
2 2 1 0 0 1 1 2 0 
3
9 
sivakumar 38 1 clerk 2 2 1 1 1 0 1 3 0 
4
0 
arunachala
m 
40 1 
electrici
an 
2 2 1 1 2 0 2 4 0 
4
1 
sahul 
hameed 
44 1 
buisene
ss 
2 3 1 0 0 1 1 3 0 
4
2 
chandran 45 1 coolie 2 3 1 0 0 1 1 3 0 
4
3 
duraisamy 47 1 
auto 
driver 
2 3 0 0 0 0 2 3 0 
4
4 
antony 48 1 
fisherm
an 
2 3 0 0 0 0 2 3 0 
4 ganesan 48 1 coolie 2 3 0 1 2 0 3 4 0 
  
 
 
     
  
5 
4
6 
hariharan 50 1 vendor 2 3 0 1 3 0 3 4 0 
4
7 
jagannatha
n 
54 1 
watchm
an 
2 4 0 0 0 1 3 4 1 
4
8 
ismail 58 1 
buisene
ss 
2 4 0 0 0 1 3 4 1 
4
9 
syed 60 1 
buisene
ss 
2 4 0 1 2 0 4 4 1 
5
0 
logannatha
n 
65 1 
watchm
an 
2 5 0 1 3 1 4 4 1 
              
 
 
  
 
         
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
    
    
 
 
      
 
  
 
 
 
 
 
 
      
 
 
 
 
